MTN -035 
 
 
 
 
Acceptability, Tolerability , and Adherence of Three  Rectal Microbicide Placebo 
Formulations  among HIV Seronegative Cisgender Men, Transgender  Men and 
Transgender Women  Who Engage in Receptive Anal Intercourse  
 
 
 
 
Microbicide Trials Network  
 
 
Funding Agencies:  
Division of AIDS, US National Institute of Allergy and Infectious Diseases  
US Eunice Kennedy Shriver National Institute of  
Child Health and Human Development  
US National Institute of Mental Health  
US National Institutes of Health  
 
 
 
Grant Numbers:  
UM1AI068633, UM1AI068615, UM1AI106707  
 
 
 
DAIDS Protocol ID : [ZIP_CODE]  
 
 
 
A Non -IND Study  
 
 
 
Protocol Chair:  José A. Bauermeister, PhD, MPH  
 
 
 
Version 1.[ADDRESS_887329] Dispensing  ................................ ................................ .....................  42 
6.6 Ancillary Study Supplies  ................................ ................................ .......................  43 
6.7 Concomitant Medications and Practices  ................................ ...............................  43 
7 STUDY PROCEDURES  ................................ ................................ ................................  43 
7.1 Pre-screening  ................................ ................................ ................................ ........  44 
7.2 Screen ing ................................ ................................ ................................ ..............  44 
7.3 Enrollment (Day 0)  ................................ ................................ ................................  [ADDRESS_887330]  ................................ ................................ ................................ .................  50 
7.6 Protocol Counseling:  Adherence and Study Product Use Counseling  .................  [ADDRESS_887331]  ........................  59 
9.4 Follow -up in Response to Observed Adverse Events  ................................ ...........  60 
9.5 Sexually Transmitted Infection/Reproductive Tract Infection  ................................  60 
9.6 HIV-1/2 Infection  ................................ ................................ ................................ ... 60 
9.7 Pregnancy  ................................ ................................ ................................ .............  60 
9.8 Criteria for Early Termination of Study Participation other than HIV -1/2 Infection 
and Pregnancy  ................................ ................................ ................................ ...... 61 
10 STATISTICAL CONSIDERATIONS  ................................ ................................ ...............  61 
10.1  Overview and General Design  ................................ ................................ ..............  61 
10.2  Study Endpoints  ................................ ................................ ................................ .... 61 
10.3  Sample Size and Power  ................................ ................................ ........................  62 
10.4  Randomization Procedures  ................................ ................................ ...................  63 
10.5  Participant Accrual and Retention  ................................ ................................ .........  63 
10.6  Data and Safety Monitoring Procedures  ................................ ...............................  63 
10.7  Data Analyses  ................................ ................................ ................................ ....... 64 
10.8  Missing Data  ................................ ................................ ................................ .........  64 
11 DATA HA NDLING AND RECORDKEEPI[INVESTIGATOR_1645]  ................................ ................................ . 65 
11.1  Data Management Responsibilities  ................................ ................................ ....... 65 
 
 
MTN -035,  Version 1.0 4  June  15, 2018  11.2  Source Documents and Access to Source Data/Documents  ................................  65 
11.3  Quality Control and Quality Assurance  ................................ ................................ . 66 
12 CLINICAL SITE OVERSIGHT  ................................ ................................ ........................  66 
13 HUMAN SUBJECTS PROTECTIONS  ................................ ................................ ...........  66 
13.1  Institutional Review Boards/Ethics Committees  ................................ ....................  66 
13.2  Protocol Registration  ................................ ................................ .............................  67 
13.3 Study Coordination  ................................ ................................ ...............................  68 
13.4  Risk Benefit Statement  ................................ ................................ .........................  68 
13.5  Informed Consent Process ................................ ................................ ....................  70 
13.6  Participant Confidentiality ................................ ................................ ......................  70 
13.7  Special Populations  ................................ ................................ ..............................  71 
13.8  Compensation  ................................ ................................ ................................ ....... 72 
13.9  Communicable Disease Reporting  ................................ ................................ ........  72 
13.10  Access to HIV -related Care ................................ ................................ ...................  72 
13.11  Study Discontinuation  ................................ ................................ ...........................  72 
14 PUBLICATION POLICY  ................................ ................................ ................................ . 73 
15 APPENDICES  ................................ ................................ ................................ ................  74 
APPENDIX I:  SCHEDULE OF STUDY VISITS AND EVALUATIONS  ................................  75 
APPENDIX II:  ALGORITHM FOR HIV TESTING FOR SCREENING AND FOLLOW -UP . 77 
APPENDIX III: SAMPLE INFORMED CO NSENT FORM (SCREENING AND 
ENROLLMENT)  ................................ ................................ ................................ ..................  78 
REFERENCES  ................................ ................................ ................................ ....................  92 
 
TABLE OF FIGURES  
 
Table 1: MTN -[ADDRESS_887332] Regimen  ................................ ................................ .........  20 
Table 2: Witepsol® H5-based suppository products currently on the market  .......................  31 
Table 3: Study Product Regimen  ................................ ................................ ........................  40 
Table 4:  Visit 1 - Screening Visit  ................................ ................................ .........................  45 
Table 5:  Visit 2 - Enrollment Visit  ................................ ................................ ........................  46 
Table 6:  Visits 3, 5 and 7 – First, Second and Third PUEV  ................................ ................  47 
Table 7:  Visits 4 and 6 – Product Switch Visits  ................................ ................................ .. 48 
Table 8:  Visit 8 – Final/Early Termination Visit  ................................ ................................ ... 49 
Table 9:  Exact 2 -sided 95% Confidence Intervals Based on Various Rates of 
Acceptability or Adherence Endpoints  ................................ ................................ .................  63 
Table 10:  Analysis of Safety Event Frequency  ................................ ................................ ... 63 
 
Figure 1: MTN -035 Study Visit Schedule  ................................ ................................ ............  20 
Figure 2: MTN -[ADDRESS_887333] Chlamydia trachomatis, Chlamydia  
CTA Clinical Trial Agreement  
CWG  Community Working Group  
DAIDS  Division of AIDS  
DAIDS PRO  DAIDS Protocol Registration Office  
DNA  deoxyribonucleic acid  
DOD  directly observed dosing  
ENR  enrollment  
FDA (US) Food and Drug Administration  
FHCRC  Fred Hutchinson Cancer Research Center  
g grams  
GC Neisseria gonorrhoeae, gonorrhea  
GCP  Good Clinical Practices  
GMP  Good Manufacturing Practices  
HCG  human chorionic gonadotropin  
HEENT  Head, Eye, Ear, Nose and Throat Examination  
HHS  (U.S.) Department of Health and Human Services  
HIV Human Immunodeficiency Virus  
HIV-1 Human Immunodeficiency Virus type 1  
HSV herpes simplex virus  
HSV-1/2 herpes simplex virus type 1/2  
IATA  International Air Transport Association  
IB Investigator’s Brochure  
ICF informed consent form  
ICH International Council  for Harmonisation  
 
 
MTN -035,  Version 1.[ADDRESS_887334] infection  
SAE serious adverse event  
 
 
MTN -035,  Version 1.0 7  June  15, 2018  SCHARP  Statistical Center for HIV/AIDS Research & Prevention  
SCR  screening  
SDMC  Statistical Data Management Center  
SMC  Study Monitoring Committee  
SOP  standard operating procedure  
SMS  short message service  
SSP study specific procedures  
STI sexually transmitted infection  
S[LOCATION_003]R  suspected, unexpected serious adverse reaction  
TGM  
TGW  transgender men  
transgender women  
UA urinalysis  
UNAIDS  
UNGASS  
UPMC  Joint United Nations Programme on HIV/AIDS  
United Nations General Assembly Special Session  
University of Pi[INVESTIGATOR_658142] -035,  Version 1.[ADDRESS_887335]., Suite 222L  
Philadelphia, PA [ZIP_CODE]  
Phone:  [PHONE_2772]  
Email: [EMAIL_2433]  
 
 
 
MTN -035,  Version 1.0 9  June  15, 2018  Site Investigator s  
 
University of Pi[INVESTIGATOR_658143] (CRS)  
 
Ken Ho, MD  
Site Investigator  
UPMC, Keystone Building, Suite [ADDRESS_887336]  
Pi[INVESTIGATOR_9109],  PA [ZIP_CODE]  [LOCATION_003] 
Phone: 412 -383-7178  
Fax: 412 -383-2900  
Email: [EMAIL_11922]  
 
 
Alabama CRS  
 
Craig Hoesley, MD  
Site Investigator  
University of Alabama at Birmingham  
[ADDRESS_887337] South, VH 201  
Birmingham, AL [ZIP_CODE] [LOCATION_003]  
Phone: 205 -934-3365  
Fax: 205 -975-3232  
Email: [EMAIL_11923]  
 
 
Bridge HIV CRS  
 
Albert Liu, MD, MPH  
Site Investigator  
Clinical Research Director  
Bridge HIV CRS  
San Francisco Department of Public Health  
[ADDRESS_887338]  
San Francisco, CA [ZIP_CODE] [LOCATION_003]  
Phone: 415 -437-7408  
Fax: 415 -431-7029  
Email: [EMAIL_2671]  
 
Blantyre CRS  
 
Taha E. Taha, PhD 
CTU PI  
[INVESTIGATOR_658144],  
[ADDRESS_887339]  
Baltimore, MD [ZIP_CODE]  
Phone: 410 -614-5255  
Fax: 410 -502-0688  
Email: [EMAIL_12532]  
 
 
MTN -035,  Version 1.[ADDRESS_887340]  
[PO_BOX]  
Blantyre, Malawi  
Phone: 265 -1875 -129  
Fax: 265 -1870 -132  
Email: [EMAIL_12533]  
 
 
Wits Reproductive Health and HIV Institute (Wits RHI) CRS  
 
Helen Vera Rees, OBE, MBBChir, MA, DRCOG, DCH  
CTU Co -PI 
[INVESTIGATOR_515816] (Wits RHI)  
[ADDRESS_887341], Hillbrow  
Johannesburg, 2001 South Africa  
Phone: 27 -11-358-5300  
Email: [EMAIL_12534]  
 
Thesla Palanee -Phillips, MMed Sci, MSc, PhD  
Site Investigator  
Wits Reproductive Health and HIV Institute (Wits RHI)  
Research Centre  
[ADDRESS_887342], Hillbrow  
Johannesburg, 2038 South Africa  
Phone: 27 -11-358-5471  
Fax: 27 -86-554-1093  
Email : [EMAIL_12535]  
 
 
Chiang Mai University (CMU) HIV Prevention CRS  
 
Suwat Chariyalertsak, MD, Dr.PH  
Site Investigator  
Research Institute for Health Sciences  
Chiang Mai University  
[PO_BOX] CMU,     
Chiang Mai  [ZIP_CODE] Thailand   
Phone: 66 53 945055  
Fax:  66 53 221849  
Email: [EMAIL_12536]  
 
 
 
 
MTN -035,  Version 1.0 11  June  15, 2018  San Miguel CRS  
 
Pedro Gonzales,  MD, MAS  
Site Investigator  
IMPACTA  – San Miguel CRS  
Calle  Putumayo No.177  
San Miguel, [ZIP_CODE] , Peru  
Phone: 51 -1- 562-1600 Ext 628 
Fax: 51 -1- 562-1600 Ext 128  
Email: [EMAIL_12537]  
 
 
 
  
 
 
MTN -035,  Version 1.0 12  June  15, 2018  US National Institutes of Health (NIH)  
 
Roberta Black, PhD  
Chief, Clinical Microbicide Research Branch  
Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID),  
National Institutes of Health (NIH) - U.S. Department of Health and Human Services (HHS)  
[ADDRESS_887343], Room 8B62, MSC 9831  
Rockville, MD [ZIP_CODE] [LOCATION_003]  
Phone: 301 -496-8199  
Email: [EMAIL_11924]  
 
Naana Cleland, MHCA  
Health Specialist, Clinical Microbicide Research Branch (CMRB)   
Prevention Sciences Program (PSP) DAIDS, NIAID  
NIH – U.S. DHHS  
[ADDRESS_887344], Room 8B27 , MSC 9831  
Rockville, MD [ZIP_CODE]  [LOCATION_003] 
Phone: 240 -292-4779  
Email: [EMAIL_10114]    
 
Jeanna Pi[INVESTIGATOR_11826], MD  
DAIDS Senior Medical Officer  
DAIDS/NIAID/NIH/HHS  
[ADDRESS_887345] , Room 8B68, MSC 9831  
Rockville, MD [ZIP_CODE] [LOCATION_003]  
Phone: 240 -292-4798  
Email: [EMAIL_5486]   
 
Dianne M. Rausch, PhD  
Director  
Division of AIDS  Research, National Institutes of Mental Health ( NIMH ) 
[ADDRESS_887346] Room 8D20, MSC 9831  
Rockville, MD [ZIP_CODE]  [LOCATION_003] 
Phone: [PHONE_13617]  
Fax: [PHONE_13618]  
Email: [EMAIL_12538]  
 
Teri Senn, PhD  
Program Chief, Psychosocial Co -morbidities of HIV Prevention and Treatment  
Division of AIDS Research, NIMH  
[ADDRESS_887347] Room 9G29  
Rockville, MD [ZIP_CODE] [LOCATION_003]  
Phone: 301 -761-7852  
Email: [EMAIL_11926]   
 
  
 
 
MTN -035,  Version 1.0 13  June  15, 2018  Microbicide Trials Network (MTN) Leadership and Operations Center (LOC)  – Pi[INVESTIGATOR_625060], MD, PhD  
Co-Principal Investigator  
[INVESTIGATOR_625061], Dept of Global Health  
[ADDRESS_887348], Box 359927  
Seattle, WA  [ZIP_CODE]  
Phone: 206 -520-3808  
Fax: [PHONE_13619]  
Email: [EMAIL_4750]   
Cindy Jacobson, PharmD  
Director of Pharmacy Affairs  
Microbicide Trials Network  
[ADDRESS_887349]  
Pi[INVESTIGATOR_9109], PA  [ZIP_CODE] [LOCATION_003]  
Phone: 412 -641-8913 
Fax: 412 -641-6170 
Email: [EMAIL_11930]   
 
 
Katherine Bunge, MD  
Protocol Safety Physician  
Magee -Womens Hospi[INVESTIGATOR_809]  
[ADDRESS_887350]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE] [LOCATION_003]  
Phone: 412 -641-3464 
Fax: 412 -641-1133 
Email: [EMAIL_4599]   
 
Luis Duran, DrPH, MPIA  
Project Manager  
Microbicide Trials Network  
[ADDRESS_887351]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE] [LOCATION_003]  
Phone: 412 -641-8539 
Fax: 412 -641-6170  
Email: [EMAIL_12539]  
  
Sharon A. Riddler, MD, MPH  
Protocol Physician  
UPMC, Keystone Building, Suite [ADDRESS_887352]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE] [LOCATION_003]  
Phone:  412 -383-1741or 412 -383-1675  
Fax: 412 -383-2900  
Email: [EMAIL_12540]  
 
Devika Singh MD, MPH  
Protocol Safety Physician  
[ADDRESS_887353]  
Jericho, VT [ZIP_CODE]  [LOCATION_003] 
Phone: [PHONE_13620] 
Email: [EMAIL_11927]  
Craig Hendrix, MD  
Director, Rectal Microbicide Program and  
Pharmacology  LC Principal Investigator  
[CONTACT_201870]  
[ADDRESS_887354], Harvey 502  
Baltimore, MD [ZIP_CODE] [LOCATION_003]  
Phone: 410 -955-9707 
Fax: 410 -955-9708 
Email: [EMAIL_5013]  
 
Sharon Hillier, PhD  
MTN Principal Investigator  
[INVESTIGATOR_625062]  
[ADDRESS_887355]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE] [LOCATION_003]  
Phone: 412 -641-8933 
Fax: 412 -641-6170 
Email: [EMAIL_5476]     
 Mei Song, PhD  
Protocol Specialist  
Microbicide Trials Network  
[ADDRESS_887356]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE] [LOCATION_003]  
Phone: 412 -641-2282 
Fax: 412 -641-6170 
Email: songm4 @mail.magee.edu  
 
 
Jennifer Thomas, MSc  
Protocol Development Manager  
Microbicide Trials Network  
[ADDRESS_887357]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE] [LOCATION_003]  
Phone: 412 -641-5579  
Fax: 412 -641-6170  
Email: [EMAIL_11929]  
  
 
 
MTN -035,  Version 1.0 14  June  15, 2018  MTN Laboratory Center (LC)  
 
Edward Livant, BSMT (ASCP), MPH  
MTN LC Research Manager  
Microbicide Trials Network  
[ADDRESS_887358]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE] [LOCATION_003]  
Phone: 412 -641-3772 
Fax: 412 -641-5290 
Email: [EMAIL_12541]  
 
Lisa Rohan , PhD  
LC Representative  
University of Pi[INVESTIGATOR_658145] -Women’s Research Institute  
[ADDRESS_887359], Room B509  
Pi[INVESTIGATOR_9109], PA  [ZIP_CODE] [LOCATION_003]  
Phone: 412 -641-6108 
Fax: 412 -641-6170 
Email: lrohan @mwri.magee.edu  
 
 
 
MTN -035,  Version 1.0 15  June  15, 2018  MTN LOC  – FHI [ADDRESS_887360]  
Durham, NC  [ZIP_CODE] [LOCATION_003]  
Phone: 919 -544-7040, Ext. [ZIP_CODE]  
Fax: 919 -544-0207  
Email: [EMAIL_12542]  
 
Sherri Johnson, MPH  
Senior Clinical Research Manager  
FHI [ADDRESS_887361], NW  
Washington, DC [ZIP_CODE] [LOCATION_003]  
Phone: 202 -884-8000, Ext. [ZIP_CODE]  
Fax: 202 -884-8844   
Email: [EMAIL_11932]  
 
Jonathan Lucas, MPH  
Senior Community Program Manager  
FHI [ADDRESS_887362]  
Durham, NC 2770 1 [LOCATION_003]  
Phone: 919 -544-7040, Ext. [ZIP_CODE]  
Fax: [PHONE_13621]  
Email: [EMAIL_11023]  
 
Nicole Macagna , MA  
Prevention Research Specialist  
FHI [ADDRESS_887363]  
Durham, NC  [ZIP_CODE] [LOCATION_003]  
Phone: 919 -544-7040, Ext. [ZIP_CODE]  
Email: [EMAIL_11933]  
  
 
 
MTN -035,  Version 1.0 16  June  15, 2018  MTN Statistical Data Management Center (SDMC)  
 
Jennifer Berthiaume, MSW, MPH  
Clinical Data Manager  
Fred Hutchinson Cancer Research Center ( FHCRC ) – Statistical Center for HIV/AIDS Research 
and Prevention ( SCHARP ) 
[ADDRESS_887364]. North, J5 -000 
[PO_BOX]  
Seattle, WA [ZIP_CODE] -1024 [LOCATION_003]  
Phone:  [PHONE_13622]  
Email: [EMAIL_12543]  
 
Elizabeth Brown , ScD 
SDMC Principal Investigator  
[INVESTIGATOR_625065]  
[ADDRESS_887365] North, M2 -C200  
[PO_BOX]  
Seattle, WA [ZIP_CODE] -1024 [LOCATION_003]  
Phone: 206 -667-1731  
Fax: 206 -667-4812  
Email: [EMAIL_4749]  
 
Holly Gundacker, MS  
Statistical Research Associate  
FHCRC -SCHARP  
[ADDRESS_887366] North, M2 -C200  
[PO_BOX]  
Seattle, WA [ZIP_CODE] -1024 [LOCATION_003]  
Phone: 206 -667-6480  
Email: [EMAIL_12544]  
 
Karen Patterson , MPH 
Program & Portfolio Manager  
FHCRC -SCHARP  
[ADDRESS_887367] North, E3 -129 
[PO_BOX]  
Seattle, WA  [ZIP_CODE] -1024 [LOCATION_003]  
Phone: 206 -667-7052 
Fax: 206 -667-4812  
Email: [EMAIL_12545]     
 
 
 
 
 
  
 
 
MTN -035,  Version 1.0 17  June  15, 2018  MTN Working Group Representative s 
 
Behavioral Research Working Group (BRWG)  
 
Alex Carballo -Diéguez, PhD  
BRWG Representative  
HIV Center for Clinical and Behavioral Studies  
NYSPI & Columbia University  
[ADDRESS_887368]., Unit 15  
[LOCATION_001], NY  [ZIP_CODE] [LOCATION_003]  
Phone: [PHONE_13623]  
Fax: [PHONE_13624]  
Email: [EMAIL_12546]  
 
 
Community Working Group (CWG)  
 
Daniel Gondwe  
CWG Representative  
Johns Hopkins University Research Project  
Chipatala Avenue  
[PO_BOX]  
Blantyre, Malawi  
Phone: 265 -1875 -128  
Fax: 265 -1870 -132  
Email: dgondwe @jhu.medcol.mw  
 
Matthew Rose  
CWG Co -Chair  
National Minority AIDS Council  
1000 Vermont NW, Suite 200  
Washington, DC [ZIP_CODE] [LOCATION_003]  
Phone: 202 -277-2777  
Email: [EMAIL_12547]  
 
 
MTN -035,  Version 1.0 18  June  15, 2018  MTN -035 
 
Acceptability, Tolerability , and Adherence of Three  Rectal Microbicide Placebo 
Formulations  among HIV Seronegative Cisgender Men, Transgender  Men and 
Transgender Women  Who Engage in Receptive Anal Intercourse  
INVESTIGATOR SIGNATURE [CONTACT_625149] 1.0; June  15, 2018  
A Study of the Microbicide Trials Network  
 
Funded by:  
[CONTACT_132804]  (DAIDS) , US National Institute of Allergy and Infectious Diseases  
US Eunice Kennedy Shriver National Institute of  Child Health and Human Development  
US National Institute of Mental Health  
US National Institutes of Health  (NIH)  
 
IND Sponsor:  
A Non -IND Study  (DAIDS Protocol ID: [ZIP_CODE] ) 
 
I, the Investigator of Record, agree to conduct this study in full accordance with the provisions 
of this protocol  and all applicable protocol -related documents. I agree to conduct this study 
in compliance with [LOCATION_002] (US) Health and Human Service regulations (45 CFR 46);  
standards of the International Council on Harmoni sation (ICH) Guideline for Good Clinical 
Practice (E6); Institutional Review Board/ Independent Ethics Committee determinations; all 
applicable in -country, state, and local laws and regulations; and other ap plicable 
requirements (e.g., NIH, DAIDS) and institutional policies.  
 
I agree to maintain MTN study records in accordance with protocol -specified protections of 
participants’ confidentiality and with site IRB/IEC policies and procedures.   Study records 
must be maintained on -site for the entire implementation period of the study and a minimum 
of at least three years after completion of research as per 45 CFR 46.115 (b).  . 
DAIDS /designee  will inform the investigator/institution as to when these documents n o longer 
need to be retained . 
 
I have read and understand the information in this protocol and will ensure that all associates, 
colleagues, and employees assisting in the conduct of the study are informed about the 
obligations incurred by [CONTACT_658168] n to the study.  
 
 
___________________________  
Name [CONTACT_262338]  
 
 
____________________________  ______________________________  
Signature [CONTACT_625150] -035,  Version 1.0 19  June  15, 2018  MTN -035 
 
Acceptability, Tolerability , and Adherence of Three  Rectal Microbicide Placebo 
Formulations  among HIV Seronegative Cisgender Men, Transgender  Men and 
Transgender Women  Who Engage in Receptive Anal Intercourse  
 
PROTOCOL SUMMARY  
 
Short Title:   Rectal Microbicide  Acceptability, Tolerability , and Adherence  
 
Funders:  Division of AIDS, NIAID, NIMH, NICHD, US NIH  
 
Protocol Chair :  José A. Bauermeister, PhD, MPH  
 
Sample Size:  MTN -035 will enroll approximately 210 participants  
 
Study Population:   HIV-uninfected cisgender men,  transgender men (TGM) and 
transgender women ( TGW ) aged 18-35 years who engage in 
receptive anal intercourse (RAI)   
 
Study site s: Sites selected by [CONTACT_658169]:  Multi-site, randomized -sequence, three -period, open label 
crossover study  
 
Study Duration:  Approximately 3.5 months  of follow -up with a projected accrual 
period of 9 -12 months  
 
Study Products:  Placebo rectal insert  
Placebo  rectal douche  
Placebo rectal suppository  
 
Study Regimen:  Participants will be randomized (1:1 :1:1:1:1 ) to study product 
sequence s A-F (see Table 1 below) . At the start of each  4-week 
product use period, they will receive  either rectal inserts , rectal 
douches , or rectal suppositories  and be instructed to use  their 
assigned study product  prior to each RAI encounter  during that 
period . Participants who do not have RAI in a given week will be 
asked to use the product without se x. There will be a [ADDRESS_887369] use periods.  
 
  
 
 
MTN -035,  Version 1.0 20  June  15, 2018  Table 1: MTN -[ADDRESS_887370] Regimen  
Sequence  N Period 1  
(4 weeks)  Washout 
period (~1 
week ) Period 2  
(4 weeks)  Washout 
period (~1 
week ) Period 3  
(4 weeks)  
A 35 Rectal insert  -- Rectal douche  -- Rectal 
suppository  
B 35 Rectal 
douche  -- Rectal 
suppository  -- Rectal insert  
C 35 Rectal 
suppository  -- Rectal insert  -- Rectal 
douche  
D 35 Rectal insert  -- Rectal 
suppository  -- Rectal 
douche  
E 35 Rectal 
douche  -- Rectal insert  -- Rectal 
suppository  
F 35 Rectal 
suppository  -- Rectal douche  -- Rectal insert  
 
Figure 1: MTN -035 Study Visit Schedule  
 
 
 
Primary Objective s:  
 
Acceptability and Tolerability  
• To evaluate the acceptability and tolerability of each study product  when applied rectally 
and used prior to RAI 
o Placebo rectal insert  
o Placebo rectal douche  
o Placebo rectal suppository  
 
Adherence  
• To evaluate adherence to each study product  prior to RAI over a 4 -week -long period  
o Placebo rectal insert  
o Placebo rectal douche  
o Placebo rectal suppository  
 

 
 
MTN -035,  Version 1.0 21  June  15, 2018  Safety  
• To evaluate  the safety of each study product when applied  rectally  and used prior to RAI  
o Placebo rectal insert  
o Placebo rectal douche  
o Placebo rectal suppository  
 
Explorato ry Objective:  
 
Relative Acceptability and Tolerability  
• To evaluate the relative acceptability and tolerability between  study product s when 
applied rectally and used prior to RAI  
o Placebo rectal insert  
o Placebo rectal douche  
o Placebo rectal suppository  
 
Primary Endpoint s: 
 
Acceptability and Tolerability  
• For each study product , participant self -report of likelihood of product use if shown to be 
effective  
 
Adherence  
• Per participant report, p ercentage of occasions when each study product  was used as 
instructed (per protocol)  
 
Safety  
• Grade 2 or higher related adverse events ( AEs) as defined by [CONTACT_658170], Corrected Version 2.1, 
July 2017, and/or Addenda 1, 2 and 3 (Female Genital [Dated November 2007], Male 
Genital [Dated November 2007] and Rectal [Clarification Dated May 2012] Grading 
Tables for Use in Microbicide Studies)  
 
Explorato ry Endpoint:  
 
Relative Acceptability and Tolerability  
• Conjoint analysis of  participant acceptability and tolerability between the three study 
products  
 
1 KEY ROLES  
 
1.1 Protocol Identification  
 
Protocol Title:   Acceptability, Tolerability , and Adherence of Three  Rectal 
Microbicide Placebo Formulations  among HIV Seronegative 
 
 
MTN -035, Version 1.0 22 June  15, 2018  
 Cisgender Men, Transgender  Men and Transgender Women  
Who Engage in Receptive Anal Intercourse   
 
Protocol Number:  MTN -035 
 
Short Title:  Rectal Microbicide  Acceptability, Tolerability , and Adherence  
 
Date:   June 15, 2018  
 
1.2 Funding Agencies  and Sponsor Identification  
 
Funding Agencies:   US Division of AIDS (DAIDS)/National Institute of Allergy and 
Infectious Diseases (NIAID ) 
National Institutes of Health (NIH)  
[ADDRESS_887371]  
Rockville , MD  [ZIP_CODE] [LOCATION_003]  
 
    US National Institute of Mental Health (NIMH)  
[ADDRESS_887372]  
Rockville, MD  [ZIP_CODE] [LOCATION_003]  
 
 US Eunice Kennedy Shriver  National Institute of Child Health 
and Human Development (NICHD)  
 Maternal and Pediatric Infectious Diseases (MPID) Branch  
[ADDRESS_887373]  
Rockville , MD  [ZIP_CODE] [LOCATION_003] 
 
Pharmaceutical Company  
Collaborator:  CONRAD  
  [ADDRESS_887374]  
  Arlington, VA [ZIP_CODE] [LOCATION_003]  
 
1.3 Medical Officer  
 
Medical Officer:   Jeanna Pi[INVESTIGATOR_11826], MD  
DAIDS/NIAID  
[ADDRESS_887375] , Room 8B68 , MSC 9831  
Rockville, MD [ZIP_CODE]  
 
1.4 Clinical Laboratories  
 
Network:   MTN Laboratory Center (LC)  
   [ADDRESS_887376].  
   Pi[INVESTIGATOR_9109], PA  [ZIP_CODE] [LOCATION_003]  
 
1.5 Data Center s 
 
 
 
MTN -035, Version 1.0 23 June  15, 2018  
 Data Center:   MTN Statistical Data and Management Center (SDMC)  
  Statistical Center for HIV/AIDS Research & Prevention 
(SCHARP)/Fred Hutchinson Cancer Research Center 
(FHCRC)  
   [ADDRESS_887377] N., LE -400  
   [PO_BOX]  
   Seattle, WA [ZIP_CODE] -1024 [LOCATION_003]  
 
Qualitative Data Center:      University of Pennsylvania  
[ADDRESS_887378] . 
Philadelphia, PA [ZIP_CODE]   
 
1.6 Study Implementation  
 
Study Operations:   MTN LOC - FHI [ADDRESS_887379]  
   Durham, NC [ZIP_CODE] [LOCATION_003]  
  
 
 
MTN -035, Version 1.0 24 June  15, 2018  
 2 INTRODUCTION  
 
2.1 Background of Rectal Microbicide Research and Study Rationale  
 
Microbicides are products that are designed to be applied to the vaginal or rectal mucosa 
with the intent of preventing the acquisition of sexually transmitted infections (STIs) 
including the human immunodeficiency virus (HIV).1 The original impetus for microbicide 
development was to provide women with options for HIV pre vention in settings where 
their partners were unwilling to use condoms for penile -vaginal intercourse . However , 
there is recognition that rectal microbicides are needed for men and women who practice 
receptive anal intercourse (RAI).  
 
RAI is associated with the highest probability for sexual acquisition of HIV infection. 
Unprotected RAI is the sexual behavior with the highest per act risk of HIV acquisition ,  
conferring approximately 10 to 20 times more risk than unprotected receptive vagi nal 
intercourse  (RVI) .2,3 Globally, transgender women  (TGW) and men who have sex with 
men (MSM) are 19 times more likely to be living with HIV compared with the general 
population.4,5  
 
Despi[INVESTIGATOR_658146] (ARV) 
treatment in the last few decades, HIV rates remain disproportionately high among MSM  
throughout the world, with  prevalence ranging  from a low of 3.0% in the Middle East and 
North Africa to a high of 25.4% in the Caribbean.6 In low and middle income countries in 
Africa, Asia and Latin America, MSM continue  to experience high rates of HIV infection.6 
7In Europe an Union/European Economic Areas, HIV diagnoses among MSM declined in 
specific countries, such as the [LOCATION_008], Belgium, Italy, the Netherlands and 
Spain, but HIV continues to increase among MSM in other EU/EEA countries, with 
substantial increases in Bulgaria, Croatia, Cyprus, Czech Republic, Hungary, Ireland, 
Lithuania, and Malta in recent years.8 In the US, according to CDC, estimated annual HIV 
infections remained stable among all gay and bisexual men during 2010 to 20 14, but with 
increase among MSM aged 25 to 34 and Hispanic/Latino MSM.9  As modeled by [CONTACT_658171] (2009), even incidence rates as low as 2 -3%, like those observed among MSM in high -
income countries between 1995 and 2005, are likely to yield prevalence rates >40% within 
[ADDRESS_887380] vulnerable MSM populations, the likelihood of HIV infection is even higher. 
For example, black MSM in the US are 15 times more likely to be HIV positive than the 
general popul ation and 8.5 times more likely than other African Americans.11 In African 
countries that crimin alize homosexual activity , black MSM are roughly 72 times more 
likely to become infected with HIV  than the general population  in the US, and over  100 
times more likely than the general population in the [LOCATION_006].11 In South Africa, rates among  
black MSM are much higher than the general population , with 43.6% HIV prevalence 
among gay participants in one study conducted in  Johannesburg and Durban , and 49% 
HIV prevalence among gay participants aged 20 -24 years old in another study .12 In 
 
 
MTN -035, Version 1.0 25 June  15, 2018  
 Kenya, the only African coun try with HIV incidence data, a nnual HIV incidence was 
reported at > 20% in Mo mbasa.6 
 
Another segment of the  population  facing disproportionately high  levels of HIV are 
transgender women (TGW) and trans gender men (TGM). One  meta -analysis estimat ed 
that HIV prevalence for TGW was 19.1%  worldwide , with 21.6% for TGW in high-income 
countries (including 22% of 2,705 TGW  sampled  in the US) and 17.7% in  middle - and 
lower-income countries.13 The same study found that the risk of HIV infection was 50 and 
46.3 times higher, respectively, among TGW than the general population of reproductive -
aged adults  in middle - and lower -income countries and in higher incom e countries . Of the 
2351 transgender people diagnosed with HIV  between 2009 and 2014 in the US, 84% 
were TGW , 15% were TGM, and < 1% identified with another gender .14 Similar to MSM, 
a meta -analysis found even higher HIV infection rates (30.8% to 56.3%) among black 
TGW  than the general TGW population .15 
 
Transgender sex workers experience even higher HIV infection rates. A systematic 
review found that overall crude HIV prevalence was 27.3% among  TGW  engaging in sex  
work, compared to 14.7% of  those not engaging in sex work.16 This same meta -analysis 
indicated that transgender sex worker s experienced significantly higher risk for HIV 
infection in comparison to all other groups (RR=1.46), particularly in comparison to female 
sex workers (RR=4.02). However, little data a bout HIV pre valence is available for TGM 
or other transgender populations.    
 
The World Health Organization (WHO) developed and encourages  the use of a 
combination approach to combat the HIV epi[INVESTIGATOR_658147], including  the gay 
and transgender communities. It  include s: comprehensive condom and lubricant 
program s, harm reduction for inject ion drug users, behavioral interventions, ARV -related 
prevention and voluntary medical male circumcision  (VMMC ), HIV testing and 
counselling, HIV treatment and care including  prevention of mother -to-child transmission  
(PMTCT ), prevention of coinfections like tuberculosis and hepatitis , prevention and 
management of mental health problems, and other general care related to sexual and 
reproductive health and nutriti on.[ADDRESS_887381] e, a 2010 cross -European Internet survey estima ted that only 25 –
50% of MS M were tested for HIV infection the previous year, compared with 60% in 
Australia  and 77% in the US.[ADDRESS_887382] also been  neglected due to limited resources and inadequate service 
quality, especially in countries where male -to-male sexual activity is stigmatized or 
criminalized .19,20 Based on a UN General Assembly Special Session (UNGASS)  report , it 
is estimated that only a third of MSM in the [ADDRESS_887383]-effective tools for prevention of HIV, STIs and unintended 
pregnancies.  But, condoms are not re adily available in some countries, especially in sub-
Saharan Africa. The Joint United Nations Programme on HIV/AIDS ( UNAIDS ) estimated 
the need for male condoms was 6 billion in 47 sub -Saharan countries in 2015 , yet only 
an estimated 2.7 billion condoms we re distributed in those countries that  year. This 
suggests over half the condom need in the region i s not  being met, with South Africa as 
the only country surpassing the condom needs of its people . And, when condoms are 
accessible, they are not consistentl y used. UNAIDS also estimated that  only three of 104 
countries with avail able data reported > 90% condom use at last sexual intercourse among 
MSM.25 
 
There is little data on condom use among transgender people worldwide, but limited 
evidence shows that condom use in this population is low. A study in Cambodia found 
that consistent condom us e by [CONTACT_658172] (40%) with female partners 
than with male partners (20 –40%), with the lowest rates of use with male partners when 
buying sex.26 Another study in Thailand found that 46.7% of MSM and 52.3% of 
transgender people  used condoms in the past three months.27 
 
Analysis of CDC’s National HIV Behavioral  Surveillance (NHBS) data suggests  that 
condom use among US MSM declined 20 % from [ADDRESS_887384] igated if the 
increases in condomless sex were associated with use of other prevention strategies, 
and found that decreased condom use was not explained by [CONTACT_658173], seropositioning, 
PrEP use or HIV treatment.34 However, another study found that condomless anal 
intercourse (AI) among its MSM and TGW participants decreased during follow -up 
regard less of whether they  received PrEP or not .35  
  
There will always be people who either prefer sex without a condom (e.g., due to 
increased sexual pleasure, erectile dysfunction, intimacy, or spontaneity), or who do not 
have the necessary autonomy to negotiate condom use with their partners (e.g., sex 
workers, adolescents and young adults , alcohol and drug users). This is evident from 
various analyses of national survey data suggesting  low condom use rates among both 
men and women who engaged in RAI  (44% among males and 11% among females  for 
most recent  RAI encounter, and 26% among males and 13% among females for past 10 
RAI encounters ).36-38 This data highlights the unrealistic expectation for  consistent 
condom use . HIV prevention alternatives are needed to accommodate  all persons at risk 
of HIV infection , particularly persons  who engage in dispropo rtionately risky  activiti es like  
RAI.  
 
Currently, there is one biomedical alternative to condoms that is approved for HIV 
prevention, the Truvada oral tablet. Truvada for oral pre -exposure prophylaxis  (PrEP ), 
when used consistently and as indicated, significantly reduces  the risk of HIV acquisition 
and is generally safe .39 Also, t reating the infected partner in an HIV-serodiscordant  couple 
 
 
MTN -035, Version 1.0 27 June  15, 2018  
 with combination antiretroviral therapy (ART) includin g Truvada can  reduce HIV 
transmission by [CONTACT_8622] 96%.[ADDRESS_887385] consistently found no association 
between PrEP use and changes in risky sexual behavior41 or hormonal contraception 
effectiveness.42,43 
 
In the iPrEx study, self-reported oral PrEP adherence  among MSM and TGW  was high 
(≥89% at week 4), but drug concentrations in participants suggested that actual 
adherence was probably lower.[ADDRESS_887386], limited awareness, 
limited regulatory approval (currently approved in only seven countries worldwide ), and 
limited availability  of both PrEP and the ancillary clinical services  needed to support its 
successful implementation .25   
 
While generally effective for use as oral PrEP, Truvada tablets  require a daily dosage 
schedule to maintain protective levels  over time .39,48 Also, while Truvada is generally safe  
for use as oral PrEP, systemic delivery of a drug increases the risk and severity  of its 
possible side effects  relative to more localized drug delivery alternatives like microbicides . 
Lastly, behaviorally and conceptually linking the taking of pi[INVESTIGATOR_3353] (a da ily prevention strategy ) 
with sexua l activity (an epi[INVESTIGATOR_658148] ) could be difficult  for those who would find a 
pericoital prevention strategy  more feasible and/or preferable . Therefore, even if readily 
available to everyone, s uch product characteristics could lead to acceptability an d 
adherence challenges for many , and do not address other STIs  that can still  be passed 
via unprotected RAI . 
 
It is important to develop a range of HIV prevention products that can serve as viable 
alternatives  and/or complements  to consistent condom use and oral PrEP , including 
formulations  able to deliver multiple drugs  (e.g., anti -HIV-1 and anti -HSV-2) in 
combination . There are many other drugs being developed for HIV prevention in various 
formulations , including intravaginal rings  (IVR) , topi[INVESTIGATOR_305049], film inserts , and 
injectables .1,49,[ADDRESS_887387] would seem  an ideal drug 
delivery mechanism from an acceptability and adherence standpoint, it is unclear if topi[INVESTIGATOR_658149] . 
 
It is crucial for drugs to be designed so that  they can be  deliver ed via  mechanism s that 
not only deliver enough drug to block HIV transmission, but are also a good behavioral fit 
with the  drug’s  intended end-users.  MTN -035 will evaluate the acceptability of three  
potential rectal microbicide formulations  – an insert , a douche , and a suppository  – that 
could be used prior to RAI  and could potentially deliver enough anti -HIV drug locally to 
prevent HIV infection  during RAI . It is believed these drug delivery mechanisms would be 
congruent with cleansing practices and behaviors regarded as normal preparations prior 
to engaging in RAI or participating  in activities  where the probability of engaging in RAI is 
high.57,58 
 
2.2 Description of Study Products   
 
2.2.1  Placebo rectal insert   
 
The placebo rectal insert is formulated as a white to off -white solid dosage form. The 
insert is small (about 1.5 cm [ 2/3 of an inch ] long and  about 0.7 cm [ 1/3 of an inch ] wide) 
and bullet -shaped . The rectal insert evaluated in this study will be a placebo product  
intended for use without an applicator.  
 
Safety  of placebo rectal insert  
 
Rapi[INVESTIGATOR_658150] -demand drug dosage 
forms: inexpensive, portable, easy to apply, discreet, user -initiated, and suitable for both 
vaginal and rectal application. CONRAD developed four placebo insert prototyp es with 
varied preparations, formulations, weights, and shapes, including the placebo insert being 
evaluated in this study .[ADDRESS_887388] parameters: bodyweight, clinical observations, macroscopic 
or microscopic tissue pathology. All observed effects were deemed t o be procedural in 
origin, not due to the test articles. The average rectal irritation index for the placebo insert 
was <1, indicating no local irritation.  Following a [ADDRESS_887389]. The placebo insert did not induce any 
noticeable effects on tissue viability ( 110% by [CONTACT_658174] y), barrier integrity (transepi[INVESTIGATOR_658151] [TEER] = 95.3%), or tissue structure.[ADDRESS_887390] -generation placebo inserts 
previously used i n CONRAD 117, a Phase 1 safety and PK study of TFV, FTC, and 
TFV/FTC vaginal inserts. Of the four products tested in CONRAD 134, Placebo Insert C 
was selected for evaluation in this study.59 The selection of Placebo Insert C was based 
on the following criteria as evaluated in the CONRAD -134 study: disintegration, 
acceptability, physiochemical stability, and preliminary cost -of-goods a nalysis. As 
compared to Placebo Inserts A, B, and D, Placebo Insert C had favorable results for all 
study benchmarks: it achieved improved disintegration and acceptability rates as 
compared to first generation inserts, showed no changes in appearance or ha rdness at 
accelerated storage conditions (40˚C/75%RH), and achieved feasibility of meeting price 
targets.  (Personal communication with CONRAD , March 23, 2018 ) 
 
Initial disintegration of the placebo insert  in CONRAD 134 occurred quickly, with median 
values of 7.5 minutes for Placebo Insert C . At 60 minutes , 67% (8/12) of Placebo Insert 
C users had less than half  the insert  visible on exam. At 45 minutes , 25% (3/12) had less 
than half visible on exam. It is expect ed the insert will disintegrate fast er during rectal use 
with the addition of intercourse , somewhere between the results seen in CONRAD 134 
and the results from in -vitro dissolution testing . In in-vitro dissolution testing at 37 °C, 
approximately 42% of the insert dissolved  by 5 minutes , approximately 94% of the insert 
dissolved by 15 minutes , and approximately 98% of the insert had dissolved by [ADDRESS_887391] long been used clinically as bowel prep arations  before procedures 
and therapeutically for constipation and int ussusception. Investigators at the University of 
Washington studied the rectal mucosal safety of various enema preparations, including 
Fleet’s Phospho -Soda, Bisacodyl (Dulcolax), and a 500 mL 0.9% (iso -osmolar, normal) 
saline enema.60 The study evaluated proc toscopic appearance, light microscopic 
appearance, and scanning and transmission electron microscopy of rectal biopsies 
obtained via sigmoidoscopy 5 to 10 cm proximal to the anus, within 10 minutes after the 
various enema agents were administered and expel led. Proctoscopi[INVESTIGATOR_897], there were no 
abnormal findings after the saline enema, but some vascular disruption was grossly 
observed after Fleet's or Bisacodyl enema in all subjects. On light microscopy, only 3 of 
21 (14%)  subjects who were given the saline en ema were seen to have abnormalities at 
 
 
MTN -035, Version 1.0 30 June  15, 2018  
 the epi[INVESTIGATOR_200071], but no abnormalities were observed in the epi[INVESTIGATOR_658152], whereas much greater microscopic epi[INVESTIGATOR_658153]'s enema (81%, or 17 of 21 biopsies)  and Bisacodyl  enema  (84%, or  21 of 25 
biopsies). Of the 3 of 21  (14%)  biopsies after saline enema that were observed to have 
an absent superficial epi[INVESTIGATOR_658154], the appearance was consistent with an abrasion 
possibly caused by [CONTACT_658175]. When the biopsies were 
evaluated by [CONTACT_658176], all 5 biopsies from subjects who had received 
the saline enema had a normal appearance, whereas the biopsies from individuals who 
had received Fleet's enema had absent goblet cell s, abnormal microvilli, or disrupted 
surface in 6 of 7  (86%)  cases. Overall, the proctoscopic and scanning electron 
microscopic appearance of rectal mucosa after saline enema was no different than that 
observed in control participants .  
 
Integrated Preclin ical/Clinical Program ( IPCP ) Microbicide Development Program’s 
(MDP ) Project 5/Aim 161 studied the safety and acceptability of t hree enema microbicide 
vehicles and was performed to elucidate the preferred osmolarity of a rectal tenofovir  
enema. In this study, investigators assessed the distribution, safety, and acceptability of 
three enema formulations: hyper -osmolar (Fleet), hypo -osmolar (distilled water), and iso -
osmolar (Normosol -R), using a crossover design. For Project 5/Aim 1, SPECT/CT 
imaging was performed after administration of radiolabeled enema product. This imaging 
showed that the iso -osmolar  enema had greater colonic distribution (up to the splenic 
flexure) and greater luminal and colonic tissue concentrations of radiolabeled product 
compared to the other 2 enema formulations ( p<0.01). Colonic biopsies were also 
performed, and demonstrated th at colonic epi[INVESTIGATOR_658155] -osmolar enema ( p<0.05) and not by [CONTACT_658177]. Lastly, in 
permeability studies of the radiolabeled diethylenetriaminepentaacetic acid  (DTPA ) [ADDRESS_887392] 
plasma area under the concentration -time curve  (AUC ) and peak concentration of 
radiolabeled enema out of the three enema types.  
 
The rectal douche evaluated in this study, an enema  filled with bottled or tap  water , is 
expected to be as safe as  the distilled water and saline enemas described  above.61,62 
 
2.2.3  Placebo rectal suppository  
 
The rectal suppository evaluat ed in this study will be  a 2 g, 3-3.8 cm (1.2 -1.5 inches) long, 
fat-based, fast-release suppository  intended for use without an applicator .  
 
Safety  of placebo rectal suppositories  
 
The suppository will consist of Witepsol® H5 (IOI Oleocehmical),  a commonly used 
suppository  base. Witepsol® H5 is a  hard fat suppository base major ly composed of 
triglycerides with 15% diglyceride and not more  than 1% monoglyceride content. 
Witepsol® suppository bases are commonly utilized in several marketed products  by 
[CONTACT_419166].  The table below lists the  Witepsol®-based suppository products 
currently on the market63: 
 
 
MTN -035, Version 1.0 31 June  15, 2018  
  
Table 2: Witepsol® H5-based s uppository products curren tly on the market  
Brand Name  [CONTACT_658208] (producer Kemwell)  
Anodesyn  Lidocaine + Allantoin  Thornton & Ross = Stada  
Asacol  Mesalazine  Warner Chilcott Actavis  
Bisacodyl  Bisacodyl  Petrus  Australia  
Bismuth  Bismuth Subgallate  Martindale  
Boots Haemorrhoid  Allantoin, Lidocaine  Boots  
Doloproct/ Ultraproct  Fluocortolon + Lidocaine  Bayer  
Dulcolax  Bisacodyl  Boehringer Ingelheim  
Canasa  Mesalamine  Allergan/Aptalis  
Eucalyptine  Codein  + Eucalyptol  Medgenix  
Febricet  Paracetamol  Hemopharm  
Flagyl  Metronidazole  Zentiva  
Germoloids  Zinc Oxide, Lidocaine  Bayer  
Imigran  Sumatriptan  [COMPANY_004]  
Jelliproct  Fluocinonid + Lidocaine  Teofarma  
Kortos  Hydrocortisone  Embil  
Mesasal  Mesalazine  [COMPANY_011]  
Morphine Sulphate  Morphine  Aurum [LOCATION_006]  
Nurofen Junior  Ibuprofen  Reckitt Benckiser (Famar)  
Procto‐Glyvenol  Tribenoside, Lidocaine  Recordati  
Salazopyrin  Sulfasalazine  [COMPANY_007]  
Tramadol Stad a Tramadol  Stada  
Uniroid HC  Hydrocortisone  + 
Cinchocaine  Chemidex ( Famar)  
Voltaren  Diclofenac  [COMPANY_001]  
Vomacur  Dimenhydrinate  Hexal  
Zofran  Ondansetron  [COMPANY_004]  
 
2.3 Acceptability of  non-gel rectal microbicide formulations   
 
2.3.1  Rectal insert s/suppositories  
 
There is  little data available on the use of rectal inserts  or suppositories specifically by 
[CONTACT_658178], TGM  and TGW . One study  assessing  rectal health and behaviors among 
896 HIV positive and negative men and women in Los Angeles and Baltimore found that  
38% (101/263) of male and 40% (85/211) of female participants reported ever using a 
rectal suppository .[ADDRESS_887393] been conducted with MSM in various countries to assess potential users’ 
preference and acceptability for various rectal microbicide delivery methods, including 
gel, cream, suppository and enema. One qualitative study in  India  found that  gel was the 
preferred formulation  among focus group participants , consistent with participants ’ use of 
water -based lubricant s.65 One survey study  in Thailand (n = 408) found that young MSM 
and TGW preferred the gel formulation over suppository  (odds ratio = 1.4, p <0.01) .66 
 
 
MTN -035, Version 1.0 32 June  15, 2018  
 Similarly, one  randomized trial in the US found  higher acceptability for a gel microbicide 
formulation  over rectal suppository (75% vs. 25%, p<0 .001, n=77).55 Lastly, a  survey 
study  (n = 350)  assessing  rectal microbicide  acceptability among MSM in Tianjin, China  
found the highest acceptability for a  formulation that “makes your rectum wetter than 
normal during sex”, while a tablet  or suppositor y formulation was viewed as more 
acceptable than a  “jelly-like” formulation .67     
   
Though suppositories are viewed as less desirable  than other formulations , they are still 
viewed  as a viable rectal microbicide  delivery  method .56 Suppositor ies are very effective 
in delivering medication to the rectum . Brown et al (1997)  compar ed suppositories against  
enemas and foams in  their deliver y of mesalazine, and only with suppositories was the 
spread of mesalazine  confined to the rectum during [ADDRESS_887394] been no  studies evaluating  suppositories specifically formulated to deliver rectal 
microbicides. For example , the suppository used in the randomized US trial mentioned 
earlier55 was much  larger (8 g, 6.4 cm [ 2.5 inches ] long) than the average adult 
suppository in the market (2 g, 3 cm [ 1.2 inches ] long) or t he suppository planned for this 
study ( 2 g, 3-3.8 cm [1.2 -1.5 inches ] long). It is expected that  suppositor ies which are 
smaller, dissolve more readily and/or are easier to insert may result in different 
acceptability ratings . 
 
2.3.2  Rectal douche s 
 
Rectal douching is a c ommon cleansing practice for cisgender  men, TGM  and TGW  who 
engage in RAI (see Section 2.4  for a review of AI-related  douching practice s). Most MSM 
who douche rectally use water or other homemade solut ions, and  most of those who use 
commercial products tend to use saline -based solutions.57,69,[ADDRESS_887395] ed in 
the US, the t ype of douching solution used varied between racial/ethnic groups , with water 
being most commonly reported by W hite participants before (73.8%) and after (64.5%) 
AI, whereas water added with salt, soap, or some other antibacterial produc t was most 
commonly reported by [CONTACT_658179] , and commercially -
prepared saline solution was  most  commonly reported by B lack participants.[ADDRESS_887396] explored the acceptability of rectal douches  among  MSM  in different 
countries. In one US  study , 63% of the m ale couples surveyed (n = 333 couples)  indicated 
a willingness to use rectal microbicides in the form of a douche before AI if prove n 
effective for HIV prevention , and this willingness did not differ significantly by [CONTACT_121814].73 
A French study  also found that 58.5% of MSM  who reported recent r ectal douche use 
were likely or very likely to use a hypothetical rectal microbicide douche for HIV 
prevention, compared to 49.2% of MSM  who did not report recent rectal douche use .74 
Similar  support for rectal microbicide douche  formulat ions has been reported  in 
develop ing countries . Galea et al (2014) conducted a focus group study with MSM in Peru 
and Ecu ador (n = 140), where  participants voiced support for a douche -based rectal 
microbicide because it could  serve as both a  clean sing and HIV prevention tool. They 
 
 
MTN -035, Version 1.0 33 June  15, 2018  
 also felt that a  douche  would provide greater protection than a lubricant as it could  go 
deeper into the body , and proposed potential drawbacks to a rectal microbicide  douche 
formulat ion including  possible discomfort from an internal cleansing, lack of time to use 
the douche prior to sex , and the inconvenience of carrying the douche around .69 
 
2.4 Practic es commonly associated with RAI  
 
One common practice associated with AI is the use of lubricant during sex. An 
international Internet -based survey found that over 59%  of respondents (n = 6124) 
reported consistent lubricant use75, while a US -based study found that 94% of MSM 
surveyed (n = 307) used lubrican t when they had anal sex and 74% used lubricant at 
least in 80% of anal sex occasions.76 In another US -based study, among young MSM  
who reported lubricant use  (n = 91) , 88% of participants used water -based products, 33% 
used silicone -based products and 14% used oil -based produc ts.[ADDRESS_887397] 
STIs and HIV because they reduce condom breakage and rectal trauma.78 However, men 
without access to water -based lubricants may sometimes use saliva, body cream o r 
petroleum jelly, which increase the risk of condom failure and viral transmission .79 Using 
lubricant without  condoms has also been linked to an increased risk of STIs.80 
 
Rectal douching is another  common practice  for cisgender men,  TGM  and TGW  who 
engage in RAI. One recent international study found that  62% of participants ( n = 1725)  
who had ever engaged in AI douched for cleansing purposes , and 83% of those (n = 
1070) douche d always or most of the time  before AI.57 Another study found that 52% of 
US MSM surveyed ( n = 4992) had douched at least once  in their lifetime , with 35% of 
respondents having douched in the last three months .[ADDRESS_887398] once in their lifetime (n = 2597), t hat same stu dy found no significant difference 
across racial/ethnic groups in prevalence of douching before RAI, but among those  who 
reported douching  after RAI (n = 711) , there was a 2 -3-fold higher likelihood of non -White 
MSM douching after RAI than White MSM (43% -56% vs. 19% , p<0.001 ). In their survey 
of Peruvian MSM and TGW, Galea and colleagues found that 18% of participants (n = 
415) reported rectal douching in the previous 6 months .71 In [LOCATION_009],  54.3% of MSM 
survey ed (n = 580) reported using a rectal douche  in the past 3 months74, while in  Brazil , 
53.4% of gay and transgender persons  interviewed who engag ed in AI in the previous 3 
months (n = 369) used a rectal douche .72  
 
One study of MSM living in [LOCATION_001] City (n = 105) found that the average age of onset 
for douching before AI was 25 years old , and that  higher proportion s of HIV -posit ive vs. 
HIV-negative MSM do uched before AI (96% [26/27] vs. 53 % [41/78]) and after AI (44% 
[12/27] vs. 27% [21/78] ).[ADDRESS_887399] identified significant associations 
between engaging in rectal douching and having HIV and/or an STI57,70,74, using 
substances  during sex57, participating in group sex74, and being “versatile”, i.e., engaging 
in both insertive and receptive AI.71 
 
Reasons for douching before RAI include : a desire to maintain personal hygiene, a desire 
to adhere  to a sexual partner’s request , a desire  to prepare or get excited for RAI,  and a 
 
 
MTN -035, Version 1.0 34 June  15, 2018  
 belief that douching enhances pleasure during RAI .57,58,69,70,81 Reasons for douching  after 
sex include : a belief  that the practice may  help protect them against STIs , a belief  that 
douching following RAI enhances pleasure , a desire to maintain personal hygiene, a 
desire to transition from sex,  and a desire  to adhere to a sexual partner’s request.58,69,70,[ADDRESS_887400] b een exposed 
 
 
MTN -035, Version 1.0 35 June  15, 2018  
 to each of the  three study products  when  applied rectally and used prior to RAI . 
 
 
3 OBJECTIVES  
 
3.1 Primary Objective s 
 
Acceptability and Tolerability  
• To evaluate the acceptability and tolerability of each study product  when applied 
rectally and used prior to RAI 
o Placebo rectal insert  
o Placebo rectal douche  
o Placebo rectal suppository  
 
Adherence  
• To evaluate adherence to each study product  prior to RAI over a 4 -week -long period  
o Placebo rectal insert  
o Placebo rectal douche  
o Placebo rectal suppository  
 
Safety  
• To evaluate  the safety of each study product when applied  rectally  and used prior to 
RAI  
o Placebo rectal insert  
o Placebo rectal douche  
o Placebo rectal suppository  
 
3.2 Explorato ry Objective  
 
Relative Acceptability and Tolerability  
• To evaluate the relative acceptability and tolerability between  study product s when 
applied rectally and used prior to RAI 
o Placebo rectal insert  
o Placebo rectal douche  
o Placebo rectal suppository  
 
 
4 STUDY DESIGN  
 
4.1 Identification of Study Design  
 
MTN -035 is a multi -site, randomized -sequence, three -period, open label crossover study . 
 
 
 
MTN -035, Version 1.0 36 June  15, 2018  
 4.2 Summary of Major Endpoints  
 
Primary Endpoint s: 
 
Acceptability and Tolerability  
• For each study product , participant self -report of likelihood of product use if shown to 
be effective  
 
Adherence  
• Per participant report, p ercentage of occasions when each study product  was used as 
instructed  (per protocol ) 
 
Safety  
• Grade 2 or higher related adverse events ( AEs) as defined by [CONTACT_133765], Corrected 
Version 2.1, July 2017, and/or Addenda 1, 2 and 3 (Female Genital [Dated November 
2007], Male Genital [Dated November 2007] and Rectal [Clar ification Dated May 
2012] Grading Tables for Use in Microbicide Studies)  
 
Explorato ry Endpoint:  
 
Relative Acceptability and Tolerability  
• Conjoint analysis of participant acceptability and tolerability between the three study 
products  
 
4.[ADDRESS_887401]  of HIV-uninfected cisgender men,  TGM  and TGW  aged 
18-35 who engage in RAI and meet the criteria outlined in Section s 5.2 and 5.3. 
 
4.4 Time to Complete Accrual  
 
The time to complete accrual is anticipated to be approximately  9-12 months .   
 
4.5 Study Groups  
 
MTN -035 will enroll approximately  210 participants  randomized  (1:1:1:1:1:1 ) to one of six 
sequence s of rectal microbicide product  application . 
 
4.6 Expected Duration of Participation  
 
Each participant will be in the  study for approximately three  and a half  month s.  The total 
duration of the study will be approximately 13-16 months.  
 
 
 
MTN -035, Version 1.0 37 June  15, 2018  
 4.7 Sites 
 
Sites selected by [CONTACT_625104] . 
 
5 STUDY POPULATION  
 
5.1 Selection of the Study Population  
 
The inclusion and exclusion criteria in Sections 5.2 and 5.3 will be used to ensure the 
appropriate selection of study participants.  
 
5.1.1  Recruitment  
 
Participants will be recruited from a variety of sources, including outpatient clinics, 
universities , community -based locations , online websites and social networking 
applications.  In addition, participants may be referred to the study from other local 
research projects and other health and social service providers .  Recruitment materials 
will be approved by [CONTACT_658180] /Independent Ethics Committees  
(IRBs /IECs ) prior to use.  Advice regarding these materials will be sought from site 
community representatives before they are submitted to the site IRB /IEC for review.  
 
5.1.2  Retention  
 
Once a participant is enrolled and randomized in MTN -035, the study site will make every 
effort to retain the participant in follow -up to minimize possible bias associated with loss -
to-follow -up. A retention rate of 95% will be targeted. The site will be responsible for 
developi[INVESTIGATOR_658156] d Operating Procedures (SOPs)  to target and 
ensure high rates of retention.  
 
5.2 Inclusion Criteria  
 
Individuals who meet the following criteria are eligible for  study  inclusion:  
 
1. Men (cis or trans gender ) and TGW  who are  18-35 years old at Screening , verified 
per site SOP  
 
2. Able and willing to provide written informed consent  
 
3. HIV-1/[ADDRESS_887402] ( IoR) or designee  
 
7. At Screening , history of consensual RAI at least three  times  in the past three 
month s and expecting to maintain at least this frequency of RAI  during study 
participation  per participant report  
 
8. Willing to not take part in other research studies involving drugs, medical devices, 
genital or rectal products, or vaccines  for the duration of study participation 
(including the time between Screening and Enrollment)  
 
9. For individuals  who can get pregnant  (i.e., TGM with a female reproductive 
system ): a negative pregnancy test at Screening and Enrollment  
 
10. For individuals  who can get pregnant : Per participant report at Enrollment, using 
an effective method of contraception for at least 30 days (inclusive) prior to 
Enrollment  and intending to use an effective method for the duration of study 
participation;  effective methods  include:  
a) Hormonal methods  
b) Intrauterine device (IUD) inserted at least 30 days prior to Enrollment 
(but not past the maximum length of re commended usage according to 
package instructions)  
c) Sterilization (of participant or , if in a monogamous relationship, of  
partner, as defined in site SOPs)  
d) Abstinence  from RVI for 90 days prior to Enrollment, and inten tion to 
abstain from RVI  for the dura tion of study participation  
 
5.3 Exclusion Criteria  
 
Individuals who meet any of the following criteria will be excluded from the study:   
 
1. At Screening:  
a) History of inflammatory bowel disease    
b) Current anorectal condition that would impede product placement or 
assessment of tolerability by [CONTACT_658181]  
 
2. Anticipated use and/or unwillingness to abstain from using non-study rectally -
administered medications and products during study participation , including 
personal lubricants containing nonoxynol -9 (N-9) 
 
Note: The use of non-study personal lubricants and usual pre -RAI douches that do not 
contain N -[ADDRESS_887403] s 
 
4. Participation in research studies involving drugs, medical devices, genital 
products, or vaccines  within 30 days of the Enrollment Visit  
 
5. Participation in research studies involving rectal products (ever)  
 
 
 
MTN -035, Version 1.[ADDRESS_887404] -exposure prophylaxis (PEP) for potential HIV 
exposure within the 3 months prior to Enrollment  
 
7. In the 3 months  prior to Enrollment , participant enga gement  in condomless RAI or 
RVI while not on PrEP with a partner who is HIV-positive and either not on ART  or 
of unknown ART use status (by [CONTACT_6270] -report)  
 
8. In the  month prior to Enrollment , participant engagement in condomless RAI or RVI 
while not on PrEP with a partner who is of unknown HIV status and unknown  
PrEP /ART  use status  (by [CONTACT_6270] -report)  
 
9. Non-therapeutic injection drug use in the 12 months prior to Enrollment  
 
10. At either Screening  or Enrollment , participant -reported symptoms and/or clinical or 
laboratory diagnosis of active anorectal or reproductive tract infection (RTI) 
requiring treatment per current WHO  guidelines 
(http://www.who.int/hiv/pub/sti/pub6/en/ ), or symptomatic urinary tract infection 
(UTI). Infections requiring treatment include Neisseria gonorrhea (GC), Chlamydia 
trachomatis (CT), syphilis, active herpes sim plex virus (HSV) lesions, anogenital 
sores or ulcers, or symptomatic genital warts , chancroid,  pelvic inflammatory 
disease (PID), symptomatic bacterial vaginosis (BV), symptomatic vaginal 
candidiasis, and  trichomoniasis . 
 
Note:  Otherwise eligible participants with a  symptomatic  UTI or an STI/RTI requiring 
treatment per current WHO guidelines  may be re -tested during the screening process  and 
if treatment is completed and symptoms have resolved within  the screening window  the 
participant may be enrol led. 
 
Note: HSV -1 or HSV -2 seropositive diagnosis with no active lesions is permitted since 
treatment is not required . 
 
11. For individuals  who can get pregnant : Pregnant or breastfeeding at either 
Screening or Enrollment or planning  to become pregnant during study participation  
 
12. For individuals  who can get pregnant : Last pregnancy outcome 90 days or less 
prior to Screening  
 
13. Has any other condition that, in the opi[INVESTIGATOR_625078]/designee, would preclude 
informed consent, make study p articipation unsafe, complicate interpretation of 
study outcome data, or otherwise interfere with achieving study objectives.  
 
5.[ADDRESS_887405] not take part in other research 
studies involving drugs, medical devices, genital  or rectal products, or vaccines after the 
Screening Visit and while taking part in MTN -035 unless approved by [CONTACT_658182] ( PSRT ).  Participation in the following types of studies may be allowed at 
the discretion of the IoR/designee:  
 
 
 
MTN -035, Version 1.0 40 June  15, 2018  
 • Participants may take part in ancillary studies if approved by [CONTACT_625105] -035 PSRT  
• Participants who become infected with H IV may take part in observational and/or 
interventional studies for HIV -positive persons  
 
Should any participant report concurrent participation in contraindicated studies after 
enrolling in MTN -035, the IoR/designee will consult the PSRT regarding ongoing  product 
use and other potential safety considerations associated with co -enrollment.  
 
 
[ADDRESS_887406] admini stration sequences 
(Sequence A -F).  Each sequence will consist of three four-week periods of study product 
administration , with one week between each four -week period .  The duration of product 
administration including the two washout periods is approximately 14 weeks.   
 
Table 3: Study Product Regimen  
Sequence  N Period 1  
(4 weeks)  Washout 
period (~1 
week ) Period 2  
(4 weeks)  Washout 
period (~1 
week ) Period 3  
(4 weeks)  
A [ADDRESS_887407] that includes placebo inserts, placebo 
suppositories, and  placebo (water) douches  for pericoital rectal administration .  The 
products will be administered in order of the assigned sequence. It is recommended that 
participants  insert one dose of the study product between [ADDRESS_887408] should 
be administered following the participant’s usual pre -RAI practices. If a participan t does 
not engage in RAI in a given week, they will be asked to insert a dose of  the product in 
the absence of RAI . Participants will self-administer the first dose of each product  in the 
clinic to ensure correct administration and tolerability . 
 
 
MTN -035, Version 1.[ADDRESS_887409] s should be stored at controlled room temperature 20° - 25°C ( 68° - 77°F)  
until dispensed for use .  Excursions between 15°  – 30°C (59°  – 86°F)  are allowed . 
 
6.3.1  Placebo  rectal  insert  
 
The placebo rectal insert is formulated into white to off -white uncoated solid dosage forms 
in a bullet shape. Th e insert contains the following inactive excipi[INVESTIGATOR_840]: isomalt, xylitol,  
sodium CMC,  povidone, hydroxypropyl methylcellulose, poloxamer 188, sodium stearyl 
fumarate and magnesium stearate. The insert is 1.5 cm (0.6 inches ) long, 0.7 cm (0.28 
inches)  wide,  0.6 cm (0.23 inches ) in height , and approximately 500 mg in weight . The 
rectal inser t is manufactured under current Good Manufacturing Practice (cGMP) under 
CONRAD oversight . The insert is stored in a white induction -sealed HDPE bottle along 
with polyester coil and a desiccant  at controlled room temperature (see temperature 
details above) .  
 
6.3.2  Placebo r ectal douche  
 
Participants will fill the enema bottle with approximately 120 mL of clean tap water  or 
bottled water. The enema  bottles  used in this study are  commercially available 125 mL 
enema bottles that meet  US Pharmacopeia  (USP) standards  and contain  no heavy  
metals,  no phthalates,  and are bisphenol  A (BPA) free. 
 
 
 
MTN -035, Version 1.0 42 June  15, 2018  
 6.3.3  Placebo rectal suppository  
 
The rectal suppository is approximately 3-3.8 cm (1.2 -1.5 inches) long and 2 grams in 
weight . The placebo rectal suppository consists of a Witepsol® H5 (IOI Oleochemical) 
base and contains 15% diglyceride and not more than 1% monoglyceride content . The 
rectal suppository  will be  manufactured under current Good Manufactur ing Practice 
(cGMP) . The suppository is stored at controlled room temperature (see  temperature 
details above).  
 
6.[ADDRESS_887410] Supply  
 
Placebo Rectal Insert  
 
CONRAD will oversee the manufacture of the placebo  inserts by [CONTACT_49861] (Clearwater, 
FL)  
 
Placebo Rectal Douche  
 
Participants will be provided commercially available 125 mL enema bottles with pre -
lubricated tips. Bottled water or clean tap water will be used for the rectal douc hes. Bottled 
water will be provided by [CONTACT_658183].  Supplies and instructions for preparing the rectal douches  will be provided to the 
study participants .  
 
Placebo Rectal Suppository  
 
The MTN will oversee the manufacture of the placebo suppositories by [CONTACT_49861] 
(Clearwater, FL).  
 
6.4.[ADDRESS_887411] Accountability  
 
The Clinical Research Site (CRS) Pharmacist of Record (PoR) is required to maintain 
complete records of the study product s received and subsequently dispensed. All unused 
study products must be returned to the MTN LOC Pharmacist aft er the study is complete 
unless otherwise instructed by [CONTACT_658184].  
 
6.[ADDRESS_887412] use period including  
Enrollment (Day 0), Visit 4 (Day 35), and Visit 6 (Day 70).  If additional supplies are needed 
between study visits, participants will be instructed to contact [CONTACT_3452].  
 
 
MTN -035, Version 1.[ADDRESS_887413]  administration periods to facilitate insertion . 
At all other visits, clinical staff will offer participants lubricant (not containing N -9) as per 
local standard of care.   
 
6.7 Concomitant Medications  and Practices  
 
Enrolled study participants may use concomitant medications during study 
participation.  All concomitant medications reported throughout the course of the study will 
be recorded in the study database . Concomitant medications include a ll prescription 
medications, over -the-counter preparations, vitamins, nutritional supplements, and herbal 
preparat ions.  
 
Use of rectally -administered non-study medications and products  is prohibited, including  
any products containing N -9. 
 
Note: The use of non -study personal lubricants  and usual pre -RAI douches  that do not contain N -
9 is permitted during study participation  
 
 
7 STUDY PROCEDURES  
 
An overview of the study visit and evaluations schedule is presented in Appendix I .  
Presented in this section is additional information on visit -specific study procedures.  
Detailed instructions to guide and standardize procedures as well as information 
regarding the study visit win dows are provided in the MTN -035 SSP Manual available at 
http://www.mtnstopshiv.org/ research/ studies . 
 
Figure 2: MTN -035 Study Visit Schedule  
 
  

 
 
MTN -035, Version 1.0 44 June  15, 2018  
 7.1 Pre-screening  
 
As part of participant outreach and recruitment strategies, study staff can pre -screen 
potential study participants at either on -site or off -site locations. During these interactions, 
study staff may explain the study to potential participants and ascertain elements of 
presumptive eligibility (e.g., willingness to use the study product s, willingness to adhere 
to the study requirements , etc.), to be confirmed at an on -site screening visit. Process 
information (e.g., number of potential participants contact[INVESTIGATOR_530], number presumptively 
eligible) may be recorded and stored at the study site in the absence of written informed 
consen t from potential participants, provided the information is collected in such a manner 
that it cannot be linked to participant identifiers, unless a waiver is granted from the local 
IRB/IEC. Procedures and documentation will comply with local IRB/IEC requirements.  
 
7.[ADDRESS_887414] up to 45 days prior to the Enrollment Visit (Day 0).  
Multiple visits may be conducted to complete all required screening procedures, if 
necessary. Written informed consent for Screening /Enrollment will be obtained before 
any screening procedures are initiated. For participants who do not meet the eligibility 
criteria, Screening will be discontinued once ineligibility is determined.   
 
Note:  If a participant is ineligible based upon a beh avioral criterion , the behavioral eligibility 
assessment may be completed in its entirety, to avoid socially desirable reporting.  
 
 
 
MTN -035, Version 1.0 45 June  15, 2018  
 Table 4:  Visit 1 - Screening Visit  
Visit 1 -Screening Visit  
Component  Procedures  
Administrative and 
Regulatory  • Obtain written informed consent  
• Assess consent form comprehension  
• Assign a unique Participant Identification (PTID) number  
• Assess eligibility  
• Collect d emographic information  
• Collect locator information  
• Provide reimbursement  
• Schedule next visit/c ontact*  
Behavioral/Counseling  • HIV pre - and post -test counseling  
• HIV/STI risk reduction counseling  
• Protocol counseling  
Clinical  • Collect  medical history  
• Collect concomitant medications  
• Perform physical examination  
• Perform rectal examination  
• Disclos e available test results  
• Treat  or prescribe treatment  for RTI/UTI, or STIs*  Laboratory  
 Pharyngeal  • Nucleic acid amplification test ( NAAT ) for GC/CT  
Urine  • NAAT for GC/CT /Trichomonas  
• Urine dipstick/culture*  
• Pregnancy test ϕ 
Blood  • HIV-1/[ADDRESS_887415]  
• Syphilis serology  
Pelvic  • NAAT for GC/CT and Trichomonas ¤ 
Anorectal  • NAAT for GC/CT  
• HSV 1/2 detection*  (at sites with capacity)  
Study Product/Supplies  • Offer condom s 
• Offer lubricant **  
* If indicated  and/or per local standard of care, ** Lubricant will be provided at product administration visits and as per  
  local standard of care at other visits, ϕ Individuals  who can get pregnant , ¤ Individuals with a vagina or neovagina  
 
 
 
MTN -035, Version 1.0 46 June  15, 2018  
 7.3 Enrollment (Day 0)  
 
The Enrollment Visit occurs  up to [ADDRESS_887416] at the 
clinic during this visit.  
 
Table 5:  Visit 2 - Enrollment Visit  
Visit 2 - Enrollment Visit  
Component  Procedures  
Administrative and Regulatory  • Review informed consent/ confirm participant ’s willingness 
to participate in study  
• Assess and confirm eligibility  
• Review/update locator information  
• Provide reimbursement  
• Schedule next visit/contact*  
• Randomization  
Behavioral/Counseling  • HIV pre - and post -test counseling  
• HIV/STI risk reduction counseling  
• Protocol counseling  
• Training in short message service ( SMS )/instant message 
(IM) Reporting System  
• Baseline b ehavioral assessment  
Clinical  • Review/update medical history  
• Review/update concomitant medications  
• Perform targeted physical examination  
• Perform rectal examination  
• Disclos e available test results  
• Treat or prescribe t reatment for RTI/UTI, or STIs*  Laboratory  
 Pharyngeal  • NAAT for GC/CT * 
Urine  • NAAT for GC/CT /Trichomonas * 
• Urine dipstick/culture*  
• Pregnancy test ϕ 
Blood  • HIV-1/[ADDRESS_887417]  
• Plasma for archive  
• Syphilis serology*  
Pelvic  • NAAT for GC/CT/Trichomonas* ¤ 
Anorectal  • NAAT for GC/CT*  
• HSV 1/2 detection*  (at sites with capacity)  
Study Product/Supplies  • Provi de study product  and study product use counseling  
• First study product application  at the clinic  
• Offer condoms  
• Offer lubricant**  
 
 
MTN -035, Version 1.0 47 June  15, 2018  
 * If indicated  and/or per local standard of care , ** Lubricant will be provided at product administration visits and as per  
  local standard of care at other visits, ϕ Individuals  who can get pregnant , ¤ Individuals with a vagina or neovagina  
 
7.4 Follow -up Visits  
 
7.4.1  Visit s 3, 5 and 7  – First , Second and Third  Product Use End Visit s (PUEV)  
 
Visit 3  – First PUEV  should  occur 4 weeks (approximately 28 days) after the Enrollment 
Visit.  Visit 5 – Second PUEV  should occur  4 weeks (approximately 28 days) after Visit 4 
– Product Switch  Visit. Visit 7 – Third PUEV should occur 4 weeks (approximately 28 
days) after Visit 6 – Product Switch  Visit.  The PSRT must be consulted regarding 
progression into the next dosing period prior to the initiation of study product for Period s 
2 and 3 , for any part icipant who has unresolved pelvic, genital  or anorectal AEs of Grade 
≥3, and any other AE that in the opi[INVESTIGATOR_658157] . 
 
Participants will complete brief, weekly short SMS /IM assessment s about their pr oduct 
use and RAI behaviors during each 4-week product use period.  Behavioral evaluations  
will be completed at the end of each product use period  at Visits 3 , 5, and 7, including  a 
brief in -depth interview (IDI) during the visit to review their SMS /IM reports . 
 
Table 6:  Visit s 3, 5 and 7  – First , Second and Third  PUEV  
Visit s 3, 5 and 7  – First , Second and Third  PUEV  
Component  Procedures  
Administrative and Regulatory  • Review/update locator information  
• Provide reimbursement  
• Schedule next visit/contact  
[CONTACT_625111]/Counseling  • HIV pre - and post -test counseling * (Required at Visit 7)  
• HIV/STI risk reduction counseling * (Required at Visit 7)  
• Protocol counseling  
• Behavioral assessment  
• Brief i n-depth interview (IDI)  
Clinical  • Review/update medical history  
• Review/update c oncomitant medications  
• Perform targeted physical examination*  
• Perform rectal examination  
• Disclos e available test results  
• Record/update AEs   
• Treat or  prescribe t reatment for RTI/UTI, or STIs*  Laborator
y 
 Pharyngeal  • NAAT for GC/CT*  (Required at Visit 7)  
Urine  • Urine dipstick/culture*  
• NAAT for GC/CT /Trichomonas * (Required at Visit 7)  
• Pregnancy test*  ϕ 
 
 
MTN -035, Version 1.0 48 June  15, 2018  
 Visit s 3, 5 and 7  – First , Second and Third  PUEV  
Component  Procedures  
Blood  • HIV-1/[ADDRESS_887418]*  (Required at Visit 7)  
• Syphilis serology*  (Required at Visit 7)  
Pelvic  • NAAT for GC/CT/Trichomonas* ¤ (Required at Visit 7)  
Anorectal  • NAAT for GC/CT*  (Required at Visit 7)  
• HSV 1/2 detection*  (at sites with capacity)  
Study Product/Supplies  • Offer condoms  
• Offer lubricant**  
* If indicated  and/or per local standard of care , ** Lubricant will be provided at product administration visits and as per  
  local standard of care at other visits, ϕ Individuals  who can get pregnant , ¤ Individuals with a vagina or neovagina  
 
7.4.2  Visit s 4 and 6  – Product Switch  Visit s 
 
The Visit 4 – Product Switch  Visit should  occur 1 week (approximately 7 days) after Visit 
3 – First PUEV . The Visit 6 – Product Switch  Visit should occur 1 week (approximately 7 
days) after Visit 5 – Second PUEV.  
 
Table 7:  Visit s 4 and 6  – Product Switch  Visit s 
Visit s 4 and 6  – Product Switch  Visit s 
Component  Procedures  
Administrative and Regulatory  • Review/update locator information  
• Provide reimbursement  
• Schedule next visit/contact  
[CONTACT_625111]/Counseling  • HIV pre - and post -test counseling*  
• HIV/STI risk reduction counseling*  
• Protocol counseling  
Clinical  • Review/update medical history  
• Review/update c oncomitant medications  
• Perform targeted physical examination*  
• Perform rectal examination * 
• Disclos e available test results  
• Record/update AEs  
• Treat or prescribe t reatment for RTI/UTI, or STIs*  Laboratory  
 Pharyngeal  • NAAT for GC/CT*  
Urine  • Urine dipstick/culture*  
• NAAT for GC/CT /Trichomonas * 
• Pregnancy test*  ϕ 
Blood  • HIV-1/[ADDRESS_887419]*  
• Syphilis serology*  
Pelvic  • NAAT for GC/CT/Trichomonas* ¤ 
Anorectal  • NAAT for GC/CT*  
• HSV 1/2 detection*  (at sites with capacity)  
 
 
MTN -035, Version 1.0 49 June  15, 2018  
 Visit s 4 and 6  – Product Switch  Visit s 
Component  Procedures  
Study Product/Supplies  • Provi de study product  and study product use counseling  
• Study product application  at the clinic  
• Offer condoms  
• Offer lubricant**  
* If indicated  and/or per local standard of care , ** Lubricant will be provided at product administration visits and as per  
  local standard of care at other visits, ϕ Individuals  who can get pregnant , ¤ Individuals with a vagina or neovagina  
 
7.4.3  Visit 8 – Final /Early Termination  Visit  
 
The Visit 8 – Final  Visit should  occur 1 week (approximately 7 days) after Visit 7 – Third  
PUEV . This visit will serve as the participant’s study termination.  
 
During  their Final  or Early Termination  Visit, participants will complete a conjoint analysis 
assessment to compare among the study products . Also, a subset of participants 
(approximately 10 per site) will be selected to complete an IDI  during this visit  to further 
explore participants’ acceptability of the study products . 
 
Table 8:  Visit 8 – Final /Early Termination  Visit  
Visit 8 – Final /Early Termination  Visit  
Component  Procedures  
Administrative and Regulatory  • Review/update locator information  
• Provide reimbursement  
Behavioral/Counseling  • HIV pre - and post -test counseling * 
• HIV/STI risk reduction counseling * 
• Behavioral assessment  
• IDI (subset)  
Clinical  • Review/update medical history  
• Review/update concomitant medications  
• Perform targeted physical examination*  
• Perform rectal examination * 
• Disclos e available test results  
• Record/update AEs  
• Treat or prescribe treatment for RTI/UTI, or STIs*  Laboratory  
 Pharyngeal  • NAAT for GC/CT * 
Urine  • Urine dipstick/culture*  
• NAAT for GC/CT /Trichomonas * 
• Pregnancy test ϕ  
Blood  • HIV-1/[ADDRESS_887420] * 
• Syphilis serology * 
Pelvic  • NAAT for GC/CT/Trichomonas *¤ 
Anorectal  • NAAT for GC/CT * 
• HSV 1/2 detection*  (at sites with capacity)  
 
 
MTN -035, Version 1.0 50 June  15, 2018  
 Visit 8 – Final /Early Termination  Visit  
Component  Procedures  
Study Product/Supplies  • Offer condoms  
• Offer lubricant**  
* If indicated  and/or per local standard of care , ** Lubricant will be provided at product administration visits and as per  
  local standard of care at other visits, ϕ Individuals  who can get pregnant , ¤ Individuals with vagina or neovagina  
 
7.[ADDRESS_887421]  
 
7.5.1  Participants Who Become Infected with HIV -1/2 
 
If a participant tests positive for HIV -1/2 after the Enrollment Visit, s/he will be referred to 
local care and treatment services and may return to the research clinic for additional 
counseling and other support services, as needed. Continued study participation would 
be of no added benefit ; thus follow -up visits will be disconti nued and the participant will 
be considered terminated from the study.  An Early Termination Visit will be  conducted, if 
the participant is willing. Participants who are taking oral PrEP for HIV prevention while 
on study and seroconvert after randomization  may be offered additional laboratory testing 
(such as HIV RNA and HIV drug resistance testing), as clinically indicated , per 
discussions between the site IoR and L C.  Please reference the MTN -035 SSP Manual 
for additional details ( www.mtnstopshiv.org /research/ studies ). 
 
7.5.[ADDRESS_887422] (s), if they are willing. Participants 
who permanently discontinue study product use for any self -initiated reason during the 
 
 
MTN -035, Version 1.[ADDRESS_887423] use period will be terminated from the study, and an Early Termination Visit 
will be conducted, if the participant is w illing. See Section 9. 8 for additional details.    
 
7.5.4  Interim Visits  
 
Interim visits may be performed at any time during the study, for the following or other 
reasons:  
 
• For administrative reasons, e.g., a participant may have questions for study staff, 
or may need to re -schedule a follow -up visit or to perform missed procedures.  
• In response to AEs and/or SAEs.  When interim contacts or visits are completed 
in response to participant reports of AEs and/or SAEs, study staff will assess the 
reported event clinically and provide or refer the participant to  appropriate medical 
care (see also Section 9 ). 
• For interim STI counseling and test ing in response to STI symptoms.  
• For interim HIV counseling and testing in response to participant report of 
symptoms consistent with acute infection or presumed exposure to HIV . 
• To provide participants with the results of confirmatory HIV test results, per the 
algorithm in Appendi x II. 
• For other reasons at participant request, e.g., social harm , to get additional study 
product . 
 
All interim contac ts and visits will be documented in participants' study records.  
 
7.6 Protocol Counseling:  Adherence  and Study Product Use Counseling  
 
At the Enrollment and Product Switch  Visits, participants will receive study product and 
study product use counseling approp riate to the visit.  Study staff will document 
dispensation of study product  and that the counseling was provided .  Protocol adherence 
counseling will be provided to study participants upon enrollment into the study.  
Counseling will be provided in accordance with standard study methods.  Counseling also 
will include reminders regarding concomitant medication and behavioral rest rictions for 
the duration of the trial .   
 
7.7 Clinical Evaluations and Procedures  
 
Physical Examination   
The physical examination will include the following assessments:  
• General appearance  
• Weight *  
• Vital signs  
 Temperature  
 Pulse  
 Blood pressure  
 Respi[INVESTIGATOR_658158] -035, Version 1.0 52 June  15, 2018  
 • Height*  
• Oral mucosa*  
• Abdomen*  
• Head, Eye, Ear, Nose and Throat (HEENT) Examination*  
• Lymph nodes*  
• Neck*  
• Heart*  
• Lungs*  
• Extremities*  
• Skin*  
• Neurological*  
• Pelvic Examination  (for individuals with a vagina or neovagina only )** 
o Visual exam  
o Speculum exam  
o Bimanual exam  
• Genital Examination  (for individuals with a penis or neopenis only )** 
o Entire penile surface  
 Glans  
 Urethral meatus  
 Internal and external foreskin (if present)  
 Shaft  
o Scrotum  
o Inguinal lymph nodes  
      * = May be omitted after Screening  Visit 
** = May be omitted if not clinically indicated  
 
Anor ectal Exam ination  
The anorectal examination may include the following:  
• Visual  exam  
• Digital  exam  
• Anoscopy  
 
Note:  Detailed information regarding the pelvic, genital , and rectal examination, as well as 
associated procedures , can be found in the MTN -035 SSP Manual . 
 
Additional clinical assessments may be performed at the discretion of the examining 
clinic al staff  in response to symptoms or illnesses present at the time of the exam.   
 
7.8 Behavioral Evaluation s 
 
All participants will respond to computer assisted self -interview s (CASI ) at the Enrollment 
Visit (Visit 2) and at the three  PUEVs  (Visits 3, 5 and 7 ), and to a conjoint analysis 
assessment at the Final Visit (Visit 8) . The assessment done at enrollment  will include, 
among other topi[INVESTIGATOR_1102], questions on participants’ prior experience s and comfort using rectal 
products , as well as douching or other rectal hygiene practices. The follow -up 
 
 
MTN -035, Version 1.[ADDRESS_887424]  and administration method , 
including participants’ perceptions of their partners’ reactions . These assessments will 
allow investigators to identify product attributes likely to challenge and/or facilitate future  
sustained use when applied rectally by [CONTACT_531432].  Suggestions for product 
improvement will also be collected.  The conjoint analysis assessment will compare  
between the three study products , including questions on participant preferences  
regarding the different formulations . 
  
Participants will a lso complete a brief weekly report of product use via SMS/IM for each 
study product. A brief  IDI is planned for all participants at the three PUEVs  (Visit s 3, 5 
and 7 ). These IDIs will review and explore participants’ responses to acceptability, 
tolerability , and adherence questions asked via SMS /IM during each product use period.   
 
Based on Behavioral Research Working Group ( BRWG ) review of SMS/IM data , 
approximately 10 participants per site will be selected and invited to complete a  longer 
IDI at the Final Visit (Visit 8). This IDI will include  questions comparing  user acceptability 
of the study products , user -centered suggestions for product design and delivery,  
acceptability and factors influenc ing product use, douching history and education, and 
experiences with the  application method s, among other topi[INVESTIGATOR_1102] . Suggestions for product 
improvement will also be collected.  The audio from the IDI will be recorded and 
transcribed for analysis. The interview notes, recording and transcript will be consid ered 
as source documentation.  
 
Major components of both CASI and IDI  assessments have been used successfully and 
validated in prior rectal microbicide trials (e.g., MTN -006, MTN -007, MTN -017) and are 
being implemented/ planned as part of MTN -026, MTN -033 and MTN -037. 
 
7.9 Laboratory Evaluations  
 
Local Laboratory  
The local laboratory will run the following, as indicated:  
 
• Pharyngeal specimens  at sites with capacity  
 NAAT for GC/CT  
• Urine specimens  
 Human chorionic gonadotropin  (hCG)  
 NAAT for  GC/CT /Trichomonas  
 Dipstick/culture  
• Blood specimens  
 HIV-1/2 testing, with confirmatory testing as needed  
 Syphilis serology  
• Vaginal specimens (fluid)  
 NAAT for GC/CT/Trichomonas  
• Anor ectal specimens  (rectal fluid)  at sites with capacity  
 NAAT for GC/CT  
 
 
MTN -035, Version 1.0 54 June  15, 2018  
  HSV 1/2 detection  
 
Laboratory Center (LC)  
•  Blood specimens  
 Plasma archive  
• Pharyngeal specimens from  sites without local capacity  
 NAAT for GC/CT  
• Anorectal specimens  (rectal fluid) from  sites without local capacity  
 NAAT for GC/CT  
 
Once all required study analyses of collected specimens are complete, any remaining 
sample may be shipped to the MTN LC for use in study -related quality assurance and 
quality control testing. If study samples will be used for assay validation or proficiency 
testing that is not study related, all parti cipant identifiers (PTID) will be removed from the 
samples prior to use.  
 
7.10 Specimen Management  
 
The study site will adhere to the standards of good clinical laboratory practice 
(https://www.niaid.nih.gov/sites/default/files/gclp.pdf ), in accordance with cur rent DAIDS 
Laboratory Requirements, MTN -035 SSP Manual 
(http://www.mtnstopshiv.org/ research/ studies  and site SOPs  for proper collection, 
processing, labeling, transport, and storage of specimens to standardize 
procedures.  Specimen collection, testing, and storage at the site laboratories will be 
documented when applicable using the Laboratory Data Management System  (LDMS) . In 
cases where laboratory results are not available due to administrative  or laboratory error, 
the site is  permitted to re -draw specimens . Further, as part of quality control, researchers 
may need to look at short pi[INVESTIGATOR_625081] -coding repetitive DNA  sequence (3 -7 base pairs) 
from blood in the event of sample mix -up. This test will only let researchers know the 
number of times this short segment is repeated and not specific genes or specific 
sequences of base pairs.  This sequence element does not cont ain any information about 
genes, therefore researchers will not be able to identify if participants are predisposed to 
specific diseases or any other genetic information based on this information.  This test will 
be an important tool for distinguishing whet her two samples collected at the same or 
different time points are likely from the same person.  The test will only be used as part of 
a sample investigation with the knowledge of the site in situations where a known or 
suspected sample mix -up has occurred.  No genetic testing (limited or genome -wide) is 
planned and all leftover samples will be destroyed after all testing related to this study is 
completed . 
 
7.11 DAIDS Laboratory Oversight  
 
All laboratories participating in DAIDS Sponsored and/or Funded Laboratories in Clinical 
Trials will adhere to the DAIDS Laboratory Policy . 
(https://www.niaid.nih.gov/research/daids -clinical -research -policies -us-labs) 
 
 
 
MTN -035, Version 1.[ADDRESS_887425] 
with contaminated needles, blood, and blood products, appropriate blood and secretion 
precautions will be employed by [CONTACT_43613][INVESTIGATOR_658159] (NIH). All biological  specimens will be transported using packaging 
mandated by [CONTACT_625113] (CFR) [ADDRESS_887426] be 
transport ed according to instructions detailed in the International Air Transport 
Association (IATA) Dangerous Goods Regulations. Biohazardous waste will be contained 
according to institutional, transportation/carrier, and all other applicable regulations.  
 
 
8 ASSESSMENT OF SAFETY  
 
8.1 Safety Monitoring  
 
The site IoR  is responsible for continuous close safety monitoring of all study participants 
and for alerting the Protocol Team if unexpected concerns arise. A sub -group of the 
Protocol Team, including the Protocol Chair, DAIDS Medical Officer, representative(s) 
from CONRAD, and Protocol Safety Physicians  will serve as the PSRT. The MTN 
Statistical Data Management Center (SDMC) prepares routine AE and clinical data 
reports for review by [CONTACT_111153], which meets via conference call approximately once per 
month or as needed  throughout the period of study implementation to review safety data, 
discuss product use management, and address any potential safety concerns.   
 
8.2 Clinical Data and Safety Review  
 
A multi -tiered safety review process will be followed for the duration of th is study. The 
study site investigators are responsible for the initial evaluation and reporting of safety 
information at the participant level and for alerting the PSRT if unexpected concerns arise. 
Participant safety is also monitored at the Network level  through a series of routine 
reviews conducted by [CONTACT_658185]. Additional reviews may be conducted at 
each of these levels as dictated by [CONTACT_625114].  
 
MTN SDMC staff will review incoming safety data on an ongoing basis. Even ts identified 
as questionable, inconsistent, or unexplained will be queried for verification.  
 
The PSRT will meet approximately every month via conference call to review clinical data 
reports generated by [CONTACT_625115]. The content, format and frequency of the clinical 
data reports will be agreed upon by [CONTACT_658186]. In addition to the routine safety data reviews, the PSRT will convene on 
an ad hoc basis to make decisions regarding the handling of any significant safety 
concerns. If necessary, experts external to the MTN representing expertise in the fields 
 
 
MTN -035, Version 1.0 56 June  15, 2018  
 of microbicides, biostatistics, HIV acquisition and medical ethics may be invited to join the 
PSRT safety review. A recommendation to pause or stop the trial ma y be made by [CONTACT_658187]/or frequency of AEs has been observed.  
 
The Study Monitoring Committee (SMC) will review participant safety data as part of its 
regular reviews (see Section 10 .6), since no Data and Safety Monitoring Board oversight 
is planned for MTN -035. The SMC may recommend that the study proceed as designed, 
proceed with design modifications, or be discontinued. Members of the SMC will be 
independent investigators with no interest (financial or otherwise) in the outcomes of this 
study. If at any time a decision is made to discontinue enrollment and/or study product 
use in all participants, the Site IoR (s) will notify the responsible IRB(s)/IEC(s)  
expeditiously.  
 
In addition to the safety monitoring, the MTN SMC will conduct interim reviews of study 
progress, including rates of participant accrual, retention, completion of primary and main 
secondary endpoint assessments, and study or lab issues.  These reviews will  take place 
approximately every [ADDRESS_887427] . As such, an AE can be an unfavorable or 
unintended sign (including an abnormal laboratory finding, for example), symptom or 
disease temporally associated with the use of an investigational product, whether or not 
considered related to the product. This d efinition is applied to all groups beginning at the 
time of enrollment (i.e., once a participant is randomized)  through  to the termination visit . 
The term “investigational product” for this study refers to the placebo rectal insert , the 
placebo (water)  rectal douche , and  the placebo rectal suppository .  
 
Study participants will be provided instructions for contact[CONTACT_658188]. In cases of potentially life -
threatening events, participan ts will be instructed to seek immediate emergency care. 
Where feasible and medically appropriate, participants will be encouraged to seek 
evaluation where a study clinician is based, and to request that the clinician be contact[CONTACT_530173]. Record s from all non -study medical providers related to untoward 
medical occurrences will be obtained whenever possible and w ith appropriate permission 
of the participant, and required data elements will be captured in the study database . All 
participants report ing an untoward medical occurrence considered related  to product use 
will be followed clinically until the occurrence resolves (returns to baseline) or stabilizes.  
 
 
 
MTN -035, Version 1.[ADDRESS_887428]. AE severity will be graded per the DAIDS Table 
for Grading Adult and Pediatric Adverse Events, Corrected Version 2. 1, July 2017 a nd/or 
Adden da 1, 2 and 3 ( Female Genital [Dated November 2007], Male Genital [Dated 
November 2007] and Rectal [Clarification Dated May 2012] Grading Tables for Use in 
Microbicide Studies) , available on the DAIDS Regulatory Support Center ( RSC ) website 
at http://rsc.tech -res.com/clinical -research -sites/safety -reporting/daids -grading -tables . 
 
For individuals  with a vagina or neovagina , please note:  
• Asymptomatic BV and asymptomatic candid a will not be reportable AEs , but  will 
be captured on the STI CRF.  
 
For individuals  who can get pregnant , please note:  
• Fetal losses (e.g., spontaneous abortions, spontaneous fetal deaths, stillbirths) will 
not be reported as A Es, but will be captured on the Pregnancy Outcome CRF.  
• Untoward maternal conditions that either result  in or result from fetal losses are 
reported as reproductive system AEs.  
 
Fecal urgency, bloating , flatulence  and bleeding  associated with rectal procedures 
deemed to be within the range of what is normally expected will not be reportable as A Es. 
Bleeding of greater quantity or longer duration than what is typi[INVESTIGATOR_2855] , per clinician 
assessment,  will be report able as an AE . 
 
8.3.2  Serious Adverse Events  
 
An SAE will be defined by [CONTACT_658189] (Version 2.0, January 2010), which is available on the DAIDS RSC website at  
http://rsc .tech -res.com/clinical -research -sites/safety -reporting/manual , as an AE that:  
 
• Results in death  
• Is life -threatening  
• Results in persistent or significant disability/incapacity  
• Is a congenital anomaly/birth defect  
• Requires inpatient hospi[INVESTIGATOR_658160]: Per ICH SAE definition, hospi[INVESTIGATOR_658161], but is an outcome of the 
event. Thus, hospi[INVESTIGATOR_633963]. The 
following are examples of hospi[INVESTIGATOR_658162] A Es: 
o Protocol -specified admission (e.g., for procedu re required by [CONTACT_18113])  
o Admission for treatment of target disease of the study, or for pre -existing condition 
(unless it is a worsening or increase in frequency of hospi[INVESTIGATOR_633964])  
o Diagnostic admission (e.g ., for a work -up of an existing condition such as 
persistent pretreatment lab abnormality)  
o Administrative admission (e.g., for annual physical)  
o Social admission (e.g., placement for lack of place to sleep)  
 
 
MTN -035, Version 1.0 58 June  15, 2018  
 o Elective admission (e.g., for elective surgery)  
 
Important medical events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_185508], based upon appropriate medical 
judgment, they may jeopardize the patient or subject and may require medical or surgical 
intervention to prevent one of the outcomes listed above.   
 
8.3.[ADDRESS_887429]  
 
Relatedness is an assessment made by a study clinician of whether or not the event is 
related to the study agent. Degrees of relatedness will be categor ized according to current 
DAIDS -approved guidelines. Per the Manual for Expedited Reporting of Adverse Events 
to DAIDS (Version 2.0, January 2010), the relationship categories that will be used for 
this study are:  
 
• Related:  There is a reasonable possibilit y that the AE may be related to the study 
agent(s)  
• Not Related:  There is not a reasonable possibility that the AE is related to the study 
agent(s)  
 
8.4 Pregnancy and Infant Outcomes  
 
Pregnant persons  are excluded from this study.  
 
8.5 Regulatory Requirements  
 
Information on all reported A Es will be included in reports to all applicable government 
and regulatory authorities. Site IoRs/designees will submit A Es and any relevant safety 
information in accordance with local regulatory requirements.  
 
8.[ADDRESS_887430] participant privacy and 
confidentiality, it is possible that participants’ involvement in the study could become 
known to others and that social harms may result. Social harms that are ju dged by [CONTACT_658190]/designee to be serious or unexpected will be reported to the PSRT and responsible 
site IRBs /IECs  according to their individual requirements.  
 
 
[ADDRESS_887431] hold/ permanent 
discontinuation of each study product are outlined in this section. In general, the 
IoR/designee has the discretion to hold use of the study product (s) at any time if s/he 
 
 
MTN -035, Version 1.[ADDRESS_887432] use would be harmful to the participant or interfere with 
treatment deemed clinically necessary. Unless otherwise specified below, the 
IoR/designee must immediately consult the PSRT for further guidance on resuming use 
of the study product (s), continuing the hold temporarily, or progressing to permanent 
discontinuation of the study product (s). The IoR/designee will document all temporary 
product holds and permanent discontinuations on applicable CRFs . 
 
Participants reporting any unresolved A Es considered related to product use at the time 
of study termination will be followed clinically until the occurrence resolves (returns to 
baseline) or stabilizes, and this information will be documented.  
 
9.[ADDRESS_887433] use by [CONTACT_658190]/designee for any of the following reasons:  
• Acquisition of HIV infection; for those who acquire HIV , study product should be 
held beginning immediately upon recognition of the first positive/ reactive HIV test  
• Pregnancy  
• Reported use of non -study rectal medications  or products, including personal 
lubricants and usual pre -RAI douches containing N -9  
 
Note: Non -study personal lubricants and usual pre -RAI douches that do not contain N -9 
are permitted  
 
• Participant is unable or unwilling to comply with required study procedures, or 
otherwise might be put at undue risk to their safety and well -being by [CONTACT_625123], according to the judgment of the IoR/designee  
 
A parti cipant will be temporarily  discontinued  from all study product use by [CONTACT_658190]/designee and a PSRT query submitted for any of the following reasons:  
• Acquisition of an anorectal STI  
 
The IoR /designee must consult the PSRT once the temporary hold is initiated. Together, 
the IoR/designee and the PSRT will discuss resuming product use, continuing the 
temporary hold, or progressing to permanent discontinuation.  
 
 
 
MTN -035, Version 1.0 60 June  15, 2018  
 9.4 Follow -up in Response to Observed Adverse Events  
 
Grade 1  or 2  
In general, a participant who develops a Grade 1 or 2 AE as defined by [CONTACT_658191], Corrected 
Version 2. 1, July 2017  or Addend a 1, 2 and  3 (Female Genital [Dated November 2007], 
Male Genital [Dated November 2007] and Rectal [Clarification Dated May 2012] Grading 
Tables for Use in Microbicide Studies) , regardless of relationship to study product , may 
continue product use. If the IoR/designee op ts to discontinue study product, the PSRT 
must be notified.   
 
Grade 3 or 4 
For participants who develop a Grade 3 or 4 AE as defined by [CONTACT_658170], Corrected Version 2. 1, 
July 2017 or Addend a 1, 2 and  3 (Female Genital [Dated November 2007], Male Genital 
[Dated November 2007] and Rectal [Clarification Dated May 2012] Grading Tables for 
Use in Microbicide Studies) , study product must be held and the IoR  must consult with 
PSRT regarding continued use of that study product and progression to other study 
products .    
 
9.5 Sexually Transmitted Infection/Reproductive Tract Infection  
 
The IoR/designee mus t manage STI/RTI per current WHO  guidelines, available at 
http://www.who.int/hiv/pub/sti/pub6/en/ .   
 
Per Section 9.3, acquisition of an anorectal STI will lead to a temporary product hold. 
Product  use need not be held in the event of other types of  STI/RTI requiring treatment, 
unless other temporary product hold/p ermanent discontinuation guidelines described 
elsewhere in Section 9  apply.  Should the IoR/designee determine that a temporary 
product hold is warranted  due to an STI or RTI , consultation with the PSRT is required.  
 
9.6 HIV-1/[ADDRESS_887434] positive for HIV -1/[ADDRESS_887435] held immediately  by 
[CONTACT_625122]/designee.  A participant who is confirmed to be HIV -1/[ADDRESS_887436] discontinued, all fol low-up visits will be discontinued 
and the participant will be considered terminated from the study, as per Section 7.5.1 . 
Guidance regarding management and referral for participants confirmed to be HIV -
positive is located in Section 13.10 . 
 
9.7 Pregnancy  
 
Participants who can get pregnant  will be encouraged to report all signs or symptoms of 
pregnancy to study staff. The IoR /designee will counsel any participant who becomes 
pregnant regarding possible risks to the fetus according to site SOPs. The IoR/designee 
 
 
MTN -035, Version 1.0 61 June  15, 2018  
 also will refer the participant to all applicable services; however, sites will not be 
responsible for paying for pre gnancy -related care.  
 
A participant who becomes pregnant during  the study will have study product 
discontinued and will be terminated from the study, as per Section 7.5.[ADDRESS_887437] udy Participation  other than HIV -1/2 
Infection and Pregnancy  
 
Participants may voluntarily withdraw from the study for any reason at any time. The 
IoR/designee also may withdraw participants from the study to protect their safety and/or 
if they are unwilli ng or unable to comply with required study procedures, after consultation 
with the PSRT. Participants also may be withdrawn if NIAID, MTN, government or 
regulatory authorities including the Office for Human Research Protections (OHRP), or 
site IRBs /IECs  terminate the study prior to its planned end date. Every reasonable effort 
is made to complete a final evaluation of participants who withdraw or are withdrawn from 
the study prior to completing follow -up (see details regarding the Early Termination Visit  
in Section 7 .4.3). Study staff members will record the reason(s) for all withdrawals in 
participants’ study records.  
 
  
[ADDRESS_887438] : 
 
 
 
MTN -035, Version 1.0 62 June  15, 2018  
 • Participant self -report  of likelihood of product use if shown to be effective  
 
Consistent with the primary study objective to evaluate adherence to  a placebo insert , a 
placebo douche , and a placebo suppository  when applied rectally and used prior to RAI 
over a [ADDRESS_887439] : 
 
• Per participant report, p ercentage of occasions when study product  was used as 
instructed  (per protocol)  
 
Consistent with the primary study objective to evaluate the safety  of a placebo insert , a 
placebo douche, and a placebo suppository when applied rectally and used prior to RAI, 
the following endpoints will be assessed  for each study product : 
 
• Grade 2 or higher related AEs as defined by [CONTACT_658192], Corrected Version 2.1, July 2017, 
and/or Addenda 1, 2 and 3 (Female Genital [Dated November 2007], Male Genital 
[Dated November 2007] and Rectal [Clarification Dated May 2012] Grading Tables for 
Use in Microbicide Studies)  
 
10.[ADDRESS_887440] but instead to estimate overall rates of acceptability, adherence 
and safety.  
 
10.3.1  Primary Endpoints  – Acceptability/Tolerability and  Adherence  
 
Based on previous studies we expect to observe a high rate of acceptab ility (>80%) which 
equates to 20% of participants reporting a low likelihood of us ing the product in the future 
(3 on the rating scale). Likewise, we expect to observe a high rate of participants 
reporting taking at least 90% of expected doses . 
 
The table below shows the exact confidence intervals for acceptability and adherence , 
assuming α=0.05 bas ed on the Binomial distribution and  varying rates of acceptability 
and adherence. The power to rule out <50% and <70% acceptability or adherence giv en 
the rates is also shown. Calculations assume the outcomes are observed in 200 of the 
participants (5% loss to follow -up). For example, if the true acceptability or adherence 
rate is 90%, we have 100%  power to rule out a true accep tability or adherence r ate of 
75% or lower. If we observe an 80% acceptability or adherence rate, the corresponding 
95% confidence interval (CI) will be (74%, 85%) . 
 
 
 
MTN -035, Version 1.0 63 June  15, 2018  
 Table 9:  Exact 2 -sided 95% Confidence Intervals Based on Various  Rate s of Acceptability or 
Adherence Endpoints  
Acceptability rate 
/ adherence rate  95% CI if rate 
is observed  Power to rule out 
50% if rate is true  Power to rule out 
70% if rate is true  Power to rule out 
75% if rate is true  
95% (91, 98)  100%  100%  100%  
90% (85, 94)  100%  100%  100%  
85% (79, 90)  100%  100%  93% 
80% (74, 85)  100%  90% 35% 
 
10.3.2  Primary Endpoint – Safety  
 
To characterize the statistical properties of the safety endpoint, the table below presents 
the probability of observing zero, at least one, and two or more safety endpoints among 
200 participants (allowing for the possibility of 5% dropout) assuming various “true” event 
rates.  By [CONTACT_658193] 200 participants, these 
calculations are conservative. However, safety analyses will include all enrolled 
participants.  
 
Table 10:  Analysis of Safety Event Frequency  
Event Rate  P(0 events  | n=200)  P(1 event | n=200)  P(5 events | 
n=200)  P(10 events | 
n=200)  
0.1%  82% 18% 0% 0% 
0.5%  37% 63% 0% 0% 
1% 13% 87% 5% 0% 
2% 2% 98% 37% 1% 
5% 0% 100%  97% 55% 
 
10.4 Randomization Procedures  
 
Participants will be randomly assigned with the ratio 1:1 :1:1:1:[ADDRESS_887441] udy will enroll 
approximately 210 participants . 
 
The target retention rate for each study visit is 95%. Therefore, once a participant is 
enrolled in the study, the study site will make every reasonable effort to retain the 
participant for the entire study duration so that the participant is evaluable.  
 
10.[ADDRESS_887442] oversight is planned for this study. The MTN Study 
Monitoring Committee ( SMC ) will conduct interim reviews of study progress, including 
 
 
MTN -035, Version 1.[ADDRESS_887443] approximately every 
4-6 months , or as needed .  Reviews may also be conducted on an as needed basis. At 
the time of this review, or at any other time, the SMC may recommend that the study 
proceed as designed, proceed with design modifications, or be discontinued.  
 
10.7 Data Analyses  
 
10.7.1  Prim ary Analyses  on Acceptability/Tolerability and Adherence Measures  
 
All primary analyses will be based on data from the participants with data in all three 
periods of study (participants who complete each period of the study). Baseline values 
between these participants and those participants lost to follow -up will be descr ibed and 
used to interpret the generalizability of the results. Additionally, secondary analyses will 
analyze endpoints among all participants. The adherence and acceptability/tolerability 
endpoints (defined in Section 10.3.1) will be reported with 95% CI. The purpose of this 
protocol is not to compare the placebo products; therefore, we do not plan on doing 
comparisons between products in the primary analysis.  Logistic regression models will 
be used to assess the order of product use (period effect) on acc eptability/tolerance and 
adherence.  
 
10.7.[ADDRESS_887444] will be included in 
the primary analyses of safety. Secondary analyses including the washout period may 
also be performed. The number and the percentages of participants experiencing e ach 
safety endpoint (see Section 10.2) will be tabulated by [CONTACT_30157]. Each participant will 
contribute once in each category (i.e., only for highest severity AE for each participant) 
for the calculation of event rates. Exact binomial confidence intervals will be calculated 
for each safety endpoint for each arm and Fisher’s Exact test will be used to test for 
differences in event rates between the arms.  Logistic and Poisson regression models will 
be used to assess the order of product use (period effect) on  safety endpoints.  
 
10.8 Missing Data  
 
A retention rate of 95% is targeted.   Based on previous MTN trials, minimal missing data 
is expected.   If missing data rates are higher than anticipated (over 10%), sensitivity 
analyses will be conducted to assess the impa ct of missing data on trial inference . 
Assuming missing data are ignorable,  we will use multiple imputation based on all 
available baseline predictors and available trial outcomes.  
 
 
 
 
MTN -035, Version 1.[ADDRESS_887445] EDC tool, a  data management system  compliant with the International 
Council on Harmonization (ICH) Good Clinical Practices (GCP) and US CFR guidelin es 
for electronic data capture . 
 
Audio files generated by [CONTACT_106269] -depth interviews will be transcribed and translated into 
English by [CONTACT_658194] . Once the transcripts are cleaned and 
final, both the transcripts and the interview summary sheets will be electronically 
transferred to the central study team at the University of Pennsylvania using a secure File 
Transfer Protoco l site, where they will be uploaded and managed using a qualitative 
software package. The qualitative data from MTN -[ADDRESS_887446] -protected server.  
 
11.2 Source Documents and Access to Source Data/Documents  
 
All study sites will maintain source data/documents in accordance with Requirements for 
Source Docum entation in DAIDS Funded and/or Sponsored Clinical Trials 
(https://www .niaid.nih.gov/sites/default/files/daids -sourcedocpolicy.pdf ) and the relevant 
appendix regarding source documentation 
(https://www .niaid.nih.gov/sites/default/files/sourcedocappndx.pdf ). 
 
Each IoR/designee will maintain, and store securely, complete, accurate and current 
study records throughout the study. The IoR/designee will maintain all study 
documentation for a minimum of three years after submission of the site’s final Financial 
Status Report to DAIDS, unless otherwise specified by [CONTACT_658195]. These 
documents should be retained for a longer period, however, if required by [CONTACT_21765].    
 
Study records must be maintained on site for the entire period of study implementation.  
Thereafter, instructions for record storage will be provided by [CONTACT_106898].  No study records 
may be moved to an off -site location or destroyed prior to receiving approval from DAIDS.   
 
 
 
MTN -035, Version 1.[ADDRESS_887447] quality control and quality assurance procedures in 
accordance with current DAIDS policies . 
(https://www .niaid.nih.gov/sites/default/files/qmppolicy.pdf ) 
 
 
12  CLINICAL SITE OVERSIGHT  
 
Formal clinical site oversight is not planned for this stud y. However, representatives of  
the MT N, including but not limited to the LOC, SDMC, LC and  the behavioral team , will 
review study -related documentation and procedures during the study to ensure 
compliance  with the study protocol, Good Manufacturing Practice (cGMP), Good Clinical 
Practices (GCP), good clinical laboratory practice guidelines (GCLP) and other applicable 
US, local and international regulat ory requirements . Responsible parties will do  the 
following: 
 
• Assess study facilities, staffing and the quality of study conduct  
• Verify proper collection and storage of biological specimens  
• Verify proper storage, dispensing, and accountability of investigational study 
products  
 
The IoR/designee will also allow inspection of study facilities and  study -related 
documentation by [CONTACT_658196], NIH and/or contractors of NIH , 
OHRP, CONRAD, IRBs /IECs , and other local , US or international regulatory authorities.  
These entities may also assess  implementation and documentation of internal site quality 
management procedures.  A site visit log will be maintained at the study site to document 
all visits.  
 
 
13  HUMAN SUBJECTS PROTECTIONS  
 
Site investigators will make efforts to minimize risks to participants. Participants and study 
staff members will take part in a thorough informed consent process. Before beginning 
the study, the IoR/designee will have obtained IRB/IEC approval (s). The IoR /designee 
will permit audits by [CONTACT_18121], OHRP, CONRAD, MTN LOC, IRBs /IECs , SDMC, and other 
local, US, or international  regulatory authorities , or any of their appointed agents.  
 
13.1 Institutional Review Boards/Ethics Committees  
 
The participating institution is responsible for assuring that this protocol, the associated 
site-specific informed consent forms  (ICFs) , and study -related documents (such as 
 
 
MTN -035, Version 1.0 67 June  15, 2018  
 participant education and recruitment materials) are reviewed by [CONTACT_2717]/IEC responsible 
for oversight of resear ch conducted at the study site. Any amendments to the protocol 
must be approved by [CONTACT_658197] /IECs  prior to implementation.  
 
After  the initial review and approval, the responsible IRBs /IECs  must review the study at 
least annually. Each IoR/design ee will make safety and progress reports to the IRBs /IECs  
at least annually and within three months after study termination or completion. These 
reports will include the total number of participants enrolled in the study, the number of 
participants who com pleted the study, all changes in the research activity, and all 
unanticipated problems involving risks to human subjects or others. In addition, the results 
of all SMC reviews of the study will be provided to the IRBs /IECs . The study site will 
submit docum entation of continuing review to the DAIDS Protocol Registration Office 
(PRO) in accordance with the DAIDS Protocol Registration Policy and Procedures 
Manual.  
 
13.[ADDRESS_887448] the protocol and the protocol consent forms approved, as appropriate, 
by [CONTACT_532985]/IEC and any other applicable regulatory entity (RE). Upon receiving final 
approval,  the site will submit all required protocol registration documents to the DAIDS 
PRO  at the RSC. The DAIDS PRO will review the submitted protocol registration packet 
to ensure that all the required documents have been received.  
 
Site-specific ICFs  will not be reviewed and approved by [CONTACT_68410], and the site will 
receive an Initial Registration Notification when the DAIDS PRO receives a complete 
registration packet. Receipt of an Initial Registration Notification indicates successful 
completion of the pro tocol registration process. A copy of the Initial Registration 
Notification should be retained in the site ’s regulatory files.  
 
Upon receiving final IRB/IEC and any other applicable RE approval(s) for an amendment, 
the site should implement the amendment i mmediately. The site is  required to submit an 
amendment registration packet to the DAIDS PRO at the RSC. The DAIDS PRO will 
review the submitted protocol registration packet to ensure that all the required 
documents have been received. Site -specific ICF(s)  will not  be reviewed and approved 
by [CONTACT_658198] a complete registration packet. A copy of the Amendment 
Registration Notification should be retained in the sit e's regulatory files.  
 
For additional information on the protocol registration process and specific documents 
required for initial and amendment registrations, refer to the current version of the DAIDS 
Protocol Registration Manual.  
 
 
 
MTN -035, Version 1.0 68 June  15, 2018  
 13.3 Study Coordination  
 
Study implementation will be directed by [CONTACT_3181], which may not be amended without 
prior written approval from the Protocol Chair and DAIDS Medical Officer. Study 
implementation will also be guided by a common Study-Specific Procedures ( SSP) 
Manual that provides further instructions and operational guidance on conducting study 
visits; data and forms processing; specimen collection, processing, and shippi[INVESTIGATOR_007]; AE 
assessment, management and reporting; dispensing study products and documenting 
produ ct accountability; and other study operations. Standardized study -specific training 
will be provided to the site by [CONTACT_625129], SDMC, LC and other designated members 
of the Protocol Team.  
 
Close coordination between protocol team members is necessary to track study progress, 
respond to queries about proper study implementation, and address other issues in a 
timely manner. The PSRT will address issues related to study eligibility and AE 
management and reporting as needed to assure consistent case managemen t and 
documentation. Rates of accrual, adherence, follow -up, and AE incidence will be 
monitored closely by [CONTACT_658199].  
 
13.4 Risk Benefit Statement  
 
13.4.1  Risks  
 
It is not expected that this trial will expose human subjects to unreasonable risk. 
 
Phlebotomy  
Phlebotomy may lead to excessive bleeding, discomfort, feelings of dizziness or 
faintness, bruising, swelling , venous thrombosis  and/or infection.  
 
Pharyngeal Swab  
Pharyngeal (throat) swab collection often causes a momentary gagging reflex.  
 
Rectal Exam and Fluid Collection  
Insertion of a lubricated anoscope during the rectal examination  will likely cause some 
discomfort or pressure in the rectum or anorectal area. Insertion of finger(s) in the rectum 
by a clinician during the rectal examination also will likely cause discomfort or pressure in 
the rectum or anorectal area. There is the risk of mild discomfort in addition to a slight risk 
of bleeding with the insertion of rectal swabs or sponges.  
 
Vaginal Fluid Collection  
Collection of vaginal fluid may cause discomfort or pressure in the vagina or genital area.  
 
Rectal Douche  
The main risk from administering a rectal douche  is temporary discomfort.  A hollow tube 
about the thickness of a pencil will be used to put approximately 120 mL of water  into the 
rectum and flush it out again, along with any stool that is there. There is a risk of a 
 
 
MTN -035, Version 1.0 69 June  15, 2018  
 bloated/crampi[INVESTIGATOR_262268]. The tube i s small  and will be lubricated , but it might cause some 
anal or rectal discomfort if the subject has any hemorrhoids or other painful conditions. 
There is also a remote possibility of rectal perforation associated with the use of rectal 
douche  products .    
 
Rectal products  
Side effects observed with application of rectal products in previous research studies 
include: mild rectal fullness; incontinence or diarrhea; flatulence; mild abdominal pain;  
anal discharge  and proctalgia.  
 
Other Risks  
Disclosure of HIV and STI status may cause worry, sadness or depression. Disclosure of 
HIV-positive status has been associated with depression, suicidal ideation, and denial as 
well as social isolation. Trained counselors will be available to help particip ants deal with 
these feelings.  
 
Participation in clinical research includes the risks of loss of confidentiality and discomfort 
with the personal nature of questions when discussing sexual behaviors  and other 
practices . 
 
Participants at sites where local regulatory authorities require partner notification in 
response to diagnosed STI or HIV infection could have problems in their relationships. 
Participants could also have problems in their partner relationships associated with use 
of study product .   
 
Site staff will make every effort to protect participant privacy while in the study.  Although 
the study site will make every effort to protect participant privacy and confidentiality, it is 
possible that participants' involvement in the study could become kno wn to others, and 
that social harms may result (i.e., because participants could become known as HIV -
positive or at "high risk" for HIV infection).  For example, participants could be treated 
unfairly or discriminated against, or could have problems being accepted by [CONTACT_493451]/or communities.   
 
13.4.[ADDRESS_887449] benefit. Participants and others may 
benefit in the future from information learned from this study. Specifically, information 
learned in this study may lead to the development of safe and effective interventions to 
prevent HIV acquisition and transmission. Participants also may appreciate the 
opportunity to contribute to the field of HIV prevention research.  
 
Participants will receive HIV/STI risk reduction counseling, HIV and STI testing, and 
physical  and rectal  examination s. Participants may be provided or referred for STI 
treatment free of charge . In addition,  STI testing and treatment may be offered and/or 
referrals may be provided for their partners. For other medical conditions identified as part 
of the study screening and/or follow -up procedures, participants will be referred to other 
 
 
MTN -035, Version 1.[ADDRESS_887450] 
document the informed consent process in accordance with the Requirements for Source 
Documentation in DAIDS Funded and/or Sponsored Clinical Trials 
(https:// www .niaid.nih.gov/sites/default/files/daids -sourcedocpolicy.pdf ). Participants will 
be offered  copi[INVESTIGATOR_63602].  
 
In addition to the ICF , the Protocol Team will work with study staff and community 
representatives to develop appropriate materials about the study and a standardized 
approach to the informed consent process to be implemented at the study site, which will 
be detailed in the SSP Manual.  
 
The informed consent process will cover all elements of informed consent required by 
[CONTACT_18125]. In addition, the process will specifically address the following topi[INVESTIGATOR_658163]:  
 
• The lack of efficacy of the placebo study products  
• Randomization and t he importance of participa tion in all study sequences to the 
success of the study  
• The importance of adherence to the study visit and procedures schedule  
• The potential medical risks of study participation (and what to do i f such risks are 
experienced)  
• The potential social harms associated with study participation (and what to do if 
such harms are experienced)  
• The real yet limited benefits of study participation  
• The distinction between research and clinical care  
• The right t o withdraw from the study at any time  
 
13.[ADDRESS_887451] -protected access systems. Forms, lists, 
logboo ks, appointment books, and any other listings that link participants’ identification 
numbers to identifying information will be stored in a locked file in an area with limited 
access. Participants’ study information will not be released without their writt en 
permission, except as necessary for review, monitoring, and/or auditing by [CONTACT_716]:  
 
• Representatives of the US Federal Government, including the US OHRP, NIH 
and/or contractors of the NIH, and other local , US or international regulatory 
authoritie s 
• Representatives of CONRAD, including s tudy monitors  
• Study staff  
• Site IRBs /IECs  
 
The MTN has a Certificate of Confidentiality from the US Department of Health and 
Human Services that is applicable to this study. This Certificate protects study staff from 
being compelled to disclose study -related information by [CONTACT_133099], State or local 
civil, criminal, administrative, legislative or other proceedings. It thus serves to protect the 
identity and privacy of study participants  at US -based study sites . 
 
13.[ADDRESS_887452] discontinuation will be implemented. Follow -up will be completed 
and data collected per Section 7.5.2 . During the infor med consent process, individual s 
who can get pregnant  will be informed that the study products are  not an effective method 
of contraception and the effects of the study products  on a developi[INVESTIGATOR_2987].  
 
 
 
MTN -035, Version 1.0 72 June  15, 2018  
 13.7.2  Children  
 
The NIH has mandated that children be included in research trials when appropriate. This 
study meets “Justifications for Exclusion” criteria for younger children as set forth by [CONTACT_137656]. Specifically, “i nsufficient data are available in adults to judge potential risk in 
children” and “children should not be the initial group to be involved in research studies.” 
This study does not plan to enroll children under 18 years old.  
 
13.8 Compensation  
 
Pending IRB/IEC approval, participants will be compensated for time and effort in this 
study, and/or be reimbursed for travel to study visits and time away from work. Site 
specific reimbursement amounts will be specified in the site specific ICF. 
 
13.9 Communicable Disease Rep orting  
 
Study staff will comply with local requirements to report communicable diseases , 
including HIV -1/[ADDRESS_887453] -related counseling will be provided  to all potential study participants who consent 
to undergo HIV -1/2 screening to determine their eligibility for this study, and to all enrolled 
participants at each follow -up HIV -1/[ADDRESS_887454] receive their HIV -1/[ADDRESS_887455] resul ts to take part in this 
study.   
 
13.10.2  Care for Participants Identified as HIV -Positive  
 
An individual who has been identified as infected with HIV -1/[ADDRESS_887456] positive 
for HIV after the Enrollment Visit, follow -up procedures will be performed as per Section 
7.5.1. Please refer to Section 9. 6 for further details.   
 
13.11  Study Discontinuation  
 
This study may be discontinued at any time by [CONTACT_18127], the MTN,  the OHRP, other 
government or regulatory authorities, or site IRBs /IECs . 
 
 
 
 
 
MTN -035, Version 1.0 73 June  15, 2018  
 14  PUBLICATION POLICY  
 
DAIDS/NIAID and MTN policies will govern publication of the results of this study. Any 
presentation, abstract, or manuscript will be submitted by [CONTACT_658200], DAIDS, NIAID, NIMH, and CONRAD  for review prior to 
submission.  
 
  
 
 
MTN -035, Version 1.0 74 June  15, 2018  
 15 APPENDICES  
 
  
 
 
MTN -035, Version 1.0 75 June  15, 2018  
 APPENDIX I:  SCHEDULE OF STUDY VISITS AND EVALUATIONS  
 
 Visit 1  
SCR  Visit 2  
ENR  Visits 3, 5 & 7  
PUEV 1 -3 Visits 4 & [ADDRESS_887457] Switch  
Visits  Visit 8  
Final / Early 
Term Visit  
ADMINISTRATIVE AND REGULATORY   
Informed consent (SCR/ENR)  X     
Assess consent form comprehension  X     
Review informed consent/Confirm 
participant willingness to b e in study   X    
Assign PTID  X     
Collect demographic data  X     
Assess/confirm eligibility  X X    
Collect/update l ocator information  X X X X X 
Provide reimbursement  X X X X X 
Schedule next study visit/contact  * * X X  
Randomization   X    
BEHAVIORAL/COUNSELING    
HIV pre -/post -test and HIV/STI risk 
reduction counseling  X X X 
(Required at 
Visit 7)  * * 
Protocol counseling  X X X X  
Training in SMS /IM Reporting System   X    
Behavioral assessment   X X  X 
In-depth interview  (IDI)   X (brief IDI)   X (subset)  
CLINICAL       
Collect/update m edical history  X X X X X 
Perform  physical examination  (Targeted 
after Screening Visit ) X X * * * 
Perform rectal examination  X X X * * 
Collect/update c oncomitant medications  X X X X X 
Treat for UTI/RTI/STI or refer  * * * * * 
Disclos e available test results  X X X X X 
Record/update A Es   X X X 
LABORATORY   PHARYNGEAL  
NAAT for GC/CT  X * * 
(Required at 
Visit 7)  * * URINE  NAAT for GC/CT/Trichomonas  X * * 
(Required at 
Visit 7)  * * 
Urine dipstick/culture  * * * * * 
Pregnancy test  ϕ X X * * X BLOOD  Plasma for archive   X    
Syphilis serology  X * * 
(Required at 
Visit 7)  * * 
 
 
MTN -035, Version 1.0 76 June  15, 2018  
  Visit 1  
SCR  Visit 2  
ENR  Visits 3, 5 & 7  
PUEV 1 -3 Visits 4 & [ADDRESS_887458] Switch  
Visits  Visit 8  
Final / Early 
Term Visit  
HIV-1/[ADDRESS_887459]  X X * 
(Required at 
Visit 7)  * * PELVIC  
NAAT for GC/CT/Trichomonas  ¤ X * * 
(Required at 
Visit 7)  * * ANORECTAL  HSV-1/2 detection  (at sites with 
capacity)  * * * * * 
NAAT for GC/CT  X * * 
(Required at 
Visit 7)  * * 
STUDY PRODUCT/SUPPLIES   
Provision of study product and study 
product use counseling   X  X  
Study product application  at the clinic   X  X  
Offer condoms  X X X X X 
Offer lubricant  ** ** ** ** ** 
X =Required, *  = As Indicated  and/or per local standard of care, ϕ = Individuals  who can get pregnant , ¤ = Individuals 
with a vagina or neovagina , ** Lubricant will be provided at product administration visits and as per local standard of 
care at other visits   
  
 
 
MTN -035, Version 1.0 77 June  15, 2018  
 APPENDIX II:  ALGORITHM  FOR HIV TESTING FOR  
SCREENING AND FOLLOW -UP  
 
 
START 
Immunoassay*
Sample [ADDRESS_887460] 
 
Is this a 
Screening 
Participant
?-
+ or Ind
- or Ind
+Yes+
Sample [ADDRESS_887461] - or IndNoReport as 
HIV Uninfected 
Not eligible for 
enrollment
Report  as HIV
 Infected Consult LC
Consult LC-/- or   -
 +/+ or  +/-
    + or Ind
*CLIA certified labs may perform [ADDRESS_887462]
Ind: Indeterminate test results
LC: Laboratory Center
  
 
 
MTN -035, Version 1.0 78 June  15, 2018  
 APPENDIX III: SAMPLE INFORMED CONSENT FORM  (SCREENING  AND  
ENROLLMENT)  
 
DIVISION OF AIDS, NIAID, NIH  
 
MTN -035 
 
Acceptability, Tolerability , and Adherence of Three  Rectal Microbicide Placebo 
Formulations  among HIV Seronegative Cisgender Men, Transgender  Men and 
Transgender Women  Who Engage in Receptive Anal Intercourse  
 
Version 1.0 
  
June 15, 2018  
 
PRINCIPAL INVESTIGATOR: [Site to insert]  
PHONE: [Site to insert]  
Short Title for the Study: Rectal Microbicide  Acceptability, Tolerability , and Adherence  
 
INFORMED CONSENT  
 
IMPORTANT INFORMATION ABOUT THE RESEARCH STUDY  
 
You are being asked to take part in this research study because you are a healthy, HIV -uninfected  
[SITES TO INSERT PREFERRED DESCRIPTION OF STUDY POPULATION: cisgender  man,  
transgender man (TGM),  or transgender woman  (TGW) / man who has sex with men (MSM) 
or transgender woman (TGW) ] aged 18 to 35 years old  who engages in receptive anal sex  
(penis into r ectum) . Approximately 210 people will participate in this study at multiple  sites across 
the world . The US National Institutes of Health (NIH)  sponsors this  Microbicide Trials Network 
(MTN) study. At this site, the person in charge of this study is [INSERT  NAME [CONTACT_658209]] .  
 
Important things you should know:  
• The three study products in this clinical trial are a rectal douche, a rectal suppository, and 
a rectal insert.  All three are placebo study products.  
• The purposes of the study are:  
o To find out if [SITES TO INSERT PREFERRED DESCRIPTION OF STUDY 
POPULATION: cisgender men, TGM, and TGW / MSM and TGW ] would accept 
and tolerate three different ways to potentially deliver [SITES TO INSERT 
PREFERRED DESCRIPTION: anti-HIV / antiretroviral ] dru gs into the rectum 
when used before receptive anal sex.  
o To understand whether [SITES TO INSERT PREFERRED DESCRIPTION OF 
STUDY POPULATION: cisgender men, TGM, and TGW / MSM and TGW ] would 
actually use  these three rectal products as part of their usual practices around 
receptive anal sex.  
o To evaluate if each study product is safe when applied rectally and used before 
receptive anal sex by [SITES TO INSERT PREFERRED DESCRIPTION OF 
STUDY POPULATION: cisge nder men, TGM, and TGW / MSM and TGW ].   
 
 
 
MTN -035, Version 1.0 79 June  15, 2018  
 • If you qualify and choose to participate, you will be asked to use the three rectal products 
before receptive anal sex, each for one month (4 weeks). The order in which you will use 
the three products will be decid ed by [CONTACT_3364] [SITES TO INSERT PREFERRED 
DESCRIPTION OF ‘RANDOMIZATION’ ]. Neither you nor the study staff can decide the 
order in which you use the products.  
• Once enrolled, you will be asked to attend [ADDRESS_887463] today. You will come to the clinic every four and 
five weeks. The total length of your participation in the study will be approximately three 
and a half months.  
• At some of the  clinic visits, the following will occu r: 
o A physical and/or rectal exam will  be performed;  
o Blood will  be obtained  to test for HIV and/or other sexually transmitted infections 
(STI) ; 
o Urine will be collected to test for STIs and (if applicable) pregnancy;  
o Rectal, throat, and (if applicable) vaginal swabs will  be collected  to test for STIs ;  
o You will be asked to complete a short  interview. You may also be selected to 
complete a longer interview at the final visit.  
• Some risks or discomforts from previously tested rectal products include :  
o Abdominal bloating, feeling full, or a sense of a bdominal pressure and/or pain;  
o Sudden, almost uncontrollable, need to relieve the bowels ;  
o Diarrhea (loose, frequent stools) ; 
o Passing gas from the intestinal tract;  
o Feeling a constant need to pass stools, des pi[INVESTIGATOR_625092] ; 
o Anal discharge.  
• You may not experience any direct benefit from participation in this study, but you may 
learn more about HIV and other diseases and ways to protect yourself from acquiring HIV 
or other STIs. You will also have physical  and rectal exams, receive HIV and STI 
counseling , and get referrals  for other care if needed.     
• Taking part in this research project is voluntary. You do  not have to participate and you 
can stop at any time. This will not affect the service you get at t his clinic or clinics in 
surrounding areas.  
• If you decide not to join this study, t here are other currently available methods to prevent 
sexually transmitted HIV : condom use during sex and/or the use of daily oral Truvada ® 
for pre -exposure prophylaxis ( PrEP)  or post -exposure prophylaxis (PEP) . Study staff can 
provide you with additional information about PrEP and PEP if you are interested. You 
may also join another study, if we have one and if you meet its requirements.  
 
Please take time to read this entire form and ask questions before you decide if you want to join 
this study . Once you read and understand the study and its requirements, you can decide if you 
want to join. If you do decide to take part in the study , you will sign your name [CONTACT_107517]. A 
copy of this document will be offered to you. Signing this consent form does not mean you will be 
able to join the study. You must first complete the screening tests and exams to see if you are 
eligible.   
 
It is importan t to know that for this study these three rectal products will not contain any active 
drug. This means the products we will ask you to use will not protect you from acquiring  HIV or 
any other STI s. Therefore,  you should continue us ing HIV and STI preventio n methods while in 
the study.  
 
Who will be in this research study and what will I be asked to do if I join?  
 
 
MTN -035, Version 1.0 80 June  15, 2018  
 Approximately 210 participants will be enrolled in the MTN -035 study across  7 sites, with 
approximately 30 participants enrolled at each site.  
 
If you enroll in  the study, you  will be asked to use  the three rectal products  before receptive anal 
sex, each  for one month  (4 weeks) . The douche in this study will involve spraying water from  the 
nozzle of  a bottle into your rectum. The suppository  is a sma ll, cone -shaped object that you put 
in your rectum and dissolves quickly. An insert is a small, bullet -shaped  object that you put in your  
rectum and dissolves quickly.  
 
If it seems like you can join  this study based on the tests done today , you will be as ked to come 
back for an Enrollment Visit no later than [ADDRESS_887464] of three rectal products – douche, suppository or inse rt – depending on which 
product use sequence you have been assigned to . 
 
Study Visit Schedule  
  
 
What will happen during study visits?  
 
Screening Visit :  
 
The procedures done today will take about [SITE S TO INSERT TIME] . Multiple visits may be 
conducted to complete all required screening procedures.  
 
You will:  
• Answer questions to confirm you are able and willing to join the study . 
• Answer questions about w here you live  and other questions about you , your health 
(including what medications you are taking),  and your sexual practices .   
• Provide study staff your contact [CONTACT_189953] (i.e. about how we can locate  you). 
• Talk with study staff  about STIs, HIV, HIV/STI testing, and ways to avoid HIV and other 
infections passed through sex, including the use of oral Truvada® for PrEP .   
• Talk with study staff  about the requirements of the study including, but not limited to:  
o Abstain ing from using non -study rectally -administered  medications or products 
during your participation in the study , except for personal lubricants and usual pre -
RAI douches that do not contain nonoxynol -9 (N-9). 
• Have  a physical exam . 
• Have a rectal exam. Rectal fluid will be collected using  a cotton swab  (like a Q -tip or 
earbud ) to test for STIs. 
o Study staff may  insert a short (10 cm or 3-4 inches) hollow tube called an anoscope 
inside  your rectum  as part of the rectal exam and rectal fluid collection . Study staff 

 
 
MTN -035, Version 1.0 81 June  15, 2018  
 will insert their finger(s) inside your rectum as part of the rectal exam.  You may 
feel some discomfort or pressure in your rectum or anus  from the staff person’s 
finger(s) and/or anoscope . There is a sl ight risk of bleeding with the insertion of 
rectal swabs or sponges.  
• Have  your urine  tested  for STIs and other infections . 
• [For individuals  who can get pregnant ] Have your urine  tested for pregnancy . 
o If you are pregnant you cannot join this study.  
o Staff will discuss with you ways to avoid getting pregnant . 
• Have a pharyngeal (throat) swab collected to test for STIs. 
• [For individuals with a vagina or neovagina] Have some f luids collected from your 
vagina  using a swab to test for STIs . 
• Provide  a blood sample  of about 10 ml [SITES TO MODIFY AMOUNT IF NEEDED ]: 
o To test for STIs, including HIV and syphilis.  
▪ You will be told your test results as soon as they are ava ilable.  You will 
talk with study staff about the meaning of your results, how you fe el about 
them, and learn about ways to prevent HIV and other STIs. Sometimes HIV 
tests are not clearly positive, but also not clearly negative. In that case, we 
will do more tests until we can confirm  your status. To participate in the 
study,  you must receive your HIV test results . If the test shows you have 
HIV, you cannot join the study. We will refer you to available sources of 
medical care and other services you may need. The study staff will tell you 
about other studies you may be eligibl e for, if any.  
• Be given treatment or a referral for treatment of STIs, if needed.  
• Be inform ed about other services, if needed.  
• Be given  the results of your tests, when available. It is expected that all your results will 
be available by [SITE S TO SPECIFY  TIMEFRAME] .     
• Be given male condoms , if you need them . 
• [SITE S TO SPECIFY IF PARTICIPANTS MAY  BE OFFERED LUBRICANT PER 
LOCAL STANDARD OF CARE]  
• Be reimburse d for your visit . 
• Schedule your next visit to enroll in the study, if you are willing  and eligible.  
 
If you decide not to join this study , blood and other samples collected at this visit will not be kept 
or used for any tests other than those listed above.  
 
Enrollment Visit:  
 
Your Enrollment Visit  (the visit where you enter the study) will take place up to 45 days after your 
Screening Visit . This visit  will take about [SITE S TO INSERT TIME ].  
 
You will:  
• Answer questions to confirm you are able and willing to join the study . 
• Update study staff with your contact [CONTACT_3031] (about where you live and how we can 
contact [CONTACT_10825]) . 
• Be assigned the order in which you  will use the three study products . 
• Talk with study staff about the following:  
o The instructions and procedures  of the study and how to follow the study rules , 
including  use of non -study rectal medications or products . 
o STIs, HIV, HIV/STI testing, and ways to avoid HIV and other STIs.   
 
 
MTN -035, Version 1.0 82 June  15, 2018  
 • Discuss any health or medical problems you may have had in the past or since your last 
visit (including any medications you are taking) . 
• Be asked some questions about your experience and comfort using rectal products  and 
engaging in  rectal hygiene practices  such as douching , among other things. These 
questions will be asked privately via computer.  
• Be asked to respond to weekly  electronic messages relate d to your use of the study 
product s during each  product use period.  
o You will receive instructions and training on how to receive and respond  to these 
messages at the Enrollment V isit. 
• Provide a blood sample  of about 15 ml  [SITES TO MODIFY AMOUNT IF NEEDED ]: 
o In case there’s a question about your test results at a later time  (about [ADDRESS_887465] results) .  
o To test your blood for HIV . 
• Have a physical exam . 
• Have a rectal exam . 
• [For individuals  who can get pregnant ] Have a urine test for pregnancy and discuss 
with study staff ways to avoid getting pregnant . 
• Receive  the first of three  rectal  products (douche, suppository, or insert)  that you will use 
during the study, along with instructions on how to use  and store  your assigned product . 
o You will use  your assigned study product once at the clinic under the supervision 
of study staff  to ensure you can tolerate using the product and will be able to use 
it as instructed  during the study . 
• Be given  test results, if available . 
• Be given  male condoms , if you need them . 
• Be given lubricant to assist product insertion.  
• Be reimbursed for your visit . 
• Schedule your next visit, if applicable.  
 
Product Use End  Visits ( PUEV) – Visits 3, 5, and 7 : 
 
Your PUEV s will take place approximately one month (4 weeks) after you begin using each of the 
three study products, with the first PUEV taking place approximately one month after the 
Enrollment Visit. These  visits will take between [SITES TO SPECIFY TIMEFRAME]  to complete .   
 
You w ill: 
• Update study staff with your contact [CONTACT_3031] . 
• Review the instructions and procedures  of the study and how to follow the study rules , 
including  use of non -study rectal medications or products.  
• Discuss any health or m edical problems you may have had since your last visit (including 
any medications you are taking) . 
• Discuss any problems that you may be experiencing as a result of using the study product , 
or as a result of procedures performed during the study . 
• Be asked some questions about your experience using  the study product. These 
questions will be asked privately via computer.  
• Be asked to take part in a brief interview (~15 minutes) about your responses to the 
electronic messages during the previous month o f product use. This interview will be 
conducted by [CONTACT_658201] . This interview  will be audio -recorded, but 
your responses will b e kept private and confidential . 
 
 
MTN -035, Version 1.0 83 June  15, 2018  
 • Have a rectal exam . 
• Be given  test results, if testing was done . 
• Be given  male condoms, if you need them .  
• [SITES TO SPECIFY IF PARTICIPANTS MAY BE OFFERED LUBRICANT PER 
LOCAL STANDARD OF CARE]  
• Be reimburse d for your visit . 
• Schedule your next visit or contact . 
 
On your third PUEV (Visit 7), y ou w ill also: 
• Talk with study staff about STIs , HIV, HIV/STI testing, and ways to avoid HIV and other 
STIs. 
• Provide a blood sample  of about 10 ml [SITES TO MODIFY AMOUNT IF NEEDED ] to 
test your blood for STIs , including HIV and syphilis . 
• Have  your urine  tested  for STIs and other infections . 
• Have a pharyngeal (throat) swab collected to test for STIs. 
• Provide a rectal fluid sample. This will be collected using  a swab  to test for STIs. 
• [For individuals with vagina or neovagina ] Provide a vaginal fluid sample. This will be 
collected using a swab to test for STIs.  
 
Product Switch Visits – Visits 4 and 6:  
 
Your Product Switch  Visits , Visits [ADDRESS_887466] 
and second PUEVs, Visits 3 and 5, respectively. T hese visits will take between [SITES TO 
SPECIFY TIMEFRAME]  to complete.  
 
You will:  
• Update study staff with your contact [CONTACT_3031] . 
• Review the instructions and procedures  of the study and how to follow the study rules , 
including  use of non -study rectal m edications or products.  
• Discuss any health or medical problems you may have had since your last visit (including 
any medications you are taking) . 
• Discuss any problems that you may be experiencing as a result of using the study product , 
or as a result of procedures performed during the study . 
• Receive the rectal product assigned for your next product use period, along with 
instructions on how to use and store  your assigned product.  
o You will use your assigned study product once at the clinic under the superv ision 
of study staff  to ensure you can tolerate using the product and will be able to use 
it as instructed  during the study.  
• Be given  test results , if testing was done . 
• Be given  male condoms , if you need them.  
• Be given lubricant to assist product insertion.  
• Be reimburse d for your visit . 
• Schedule your next visit or contact.  
 
Final /Early Termination Visit – Visit 8 : 
 
Your Final/Early Termination Visit  will take place approximately one week  after your third PUEV , 
Visit 7 .  This visit  will take approximately [SITE S TO SPECIFY TIMEFRAME]  to complete.   
 
 
 
MTN -035, Version 1.0 84 June  15, 2018  
 You will:  
• Update study staff with your contact [CONTACT_3031] . 
• Discuss any health or medical problems you may have had since your last visit (including 
what medications you are taking) . 
• Discuss any problems that you may be experiencing as a result of using the study product , 
or as a result of procedures performed during the study . 
• Be asked some questions to compare  your experience s using  the three study product s. 
These questions will be asked privately via computer.  
o You may also be  asked to take part in  an in-depth interview (~45 minutes) about 
your experiences using the three study products, including questions about 
product design,  application methods , product use influences , douchi ng practices , 
and suggestions for product improvement . This interview will be conducted by 
[CONTACT_658201] . This interview  will be audio -recorded, but your 
responses will b e kept private and confidential . 
• [For individuals  who can get pregnant ] Have a urine test for pregnancy and discuss 
with study staff ways to avoid getting pregnant.  
• Be reimbursed for your visit . 
• Be given test results , if available.  
• Be given  male condoms, if you need them . 
• [SITES TO SPECIFY IF PARTICIPANTS MAY BE OFFERED LUBRICANT PER 
LOCAL STANDARD OF CARE]  
 
It is important that you remember that at any time during the study, study staff can answer any 
questions you may have about the procedures mentioned above or any other aspect of this study . 
 
Other Procedures:  
In addition to the procedures listed above , it is possible that study clinicians may need to perform 
additional tests  during any of the study visits , if necessary (e.g., if you report having symptoms of 
a urinary, genital, or other infection and/or other issues).  These tests might include the following:  
• Physical exam  
• Rectal exam  
• Test pharyngeal  (throat ), rectal and/or pelvic samples for STIs 
• Test your urine for STIs or other infections  
• [For individuals who can get pregnant ] Test your urine for pregnancy  
• Test your blood for HIV and/or STIs 
• Give you treatment or refer you for treatment of STIs or other issues, if needed.  
 
You may need to provide additional samples if any of the study visit  procedures need to be 
repeated due to issue s with sample processing, testing and/or shippi[INVESTIGATOR_007]. Additional testing may 
be performed as part of quality control.  
 
It may also be necessary for additional visits to be conducted for unforeseen events. For example, 
you may be asked to come to the clinic fo r repeat or additional testing to ensure that the study 
products continue to be safe for you to use. Or you may choose to come for an additional visit for 
any unforeseen issues, questions, or counseling.  
 
Some of your specimens collected in this study may be shipped and stored outside your country 
so that study -related testing can be performed. There might be a small amount of urine, blood, or 
vaginal and rectal fluid left over after we have done all of the study related testing , including testing 
 
 
MTN -035, Version 1.0 85 June  15, 2018  
 for quality assurance and control . These leftover samples will not be  stored or used for any future 
testing, and they will be destroyed after all testing related to this study is completed.     
 
What are the possible risks, side effects, and discomforts of thi s research study?  
 
Risks from use of rectal products  
The use of any rectal  product  can cause some side effects. We do not yet know all the side effects 
of the three study products . Previously tested  rectal products  have been associated with : 
• Abdominal bloating, feeling full, or a sense of abdominal pressure and/or pain  
• A sudden, almost uncontrollable , need to relieve the bowels  
• Diarrhea (loose, frequent stools)  
• Passing gas from the intestinal tract  
• Feeling a constant need to pass stools, despi[INVESTIGATOR_658164] y bowel  
• Anal discharge  
• Proctalgia (anal pain)  
 
Risks from phlebotomy (blood tests)   
• You may feel d iscomfort  
• You may feel dizzy or faint  
• You may have a bruise, swelling, small clot, or infection where the needle goes in your 
arm  
• You may have excessive ble eding  
 
Risks of throat swab  
• A pharyngeal (throat) swab often causes a momentary gagging reflex  (feeling like you 
want to vomit ). 
 
Risks of rectal douching  
• The main risk from rectal douching  is temporary discomfort. An enema bottle  will be used 
to administer about 120 -125 mL (i.e., 4 ounces or 8 tablespoons) of water  into the rectum.  
• You may experience some mild discomfort and a bloated or “crampy” feeling.  
• If you have any hemorrhoids or other painful conditions, you might feel an al or rectal 
discomfort.  
• Some air may be pumped into the rectum as well, causing flatulence  (feeling like you need 
to pass gas) .   
• There is a remote possibility of rectal perforation.  
 
Risks of rectal exams  
• During rectal exams and collection of rectal fluid samples, insertion of the study staff’s 
finger(s) and/or insertion of a lubricated anoscope will likely cause mild discomfort.  
 
Risks of rectal swab/sponge insertion  
• Insertion of rectal swabs or sponges ma y cause mild discomfort, in addition to a slight risk 
of bleeding.  
 
(For individuals  with a vagina or neovagina ) Risks of vaginal swab  
• During vaginal fluid collection, you may feel discomfort or pressure in your vagina or 
genital area.  
 
 
 
MTN -035, Version 1.0 86 June  15, 2018  
 Other Possible Risk s 
• You may become embarrassed and/or worried when discussing your sexual practices, 
ways to protect against HIV and other infections passed through sex, and your test results.  
• You may feel anxious while waiting for your test results, and after receiving the m. Trained 
study counselors will help you deal with any feelings or questions you have.  
• Finding out your HIV status could also cause problems between you and your partner(s). 
If you have any problems, study counselors will talk with you and/or your partner  to try to 
help resolve them.  
• Disclosure of your HIV and STI status may cause worry, sadness or depression. 
Disclosure of HIV -positive status has been associated with depression, suicidal ideation, 
and denial as well as social isolation.  
• It is possible that others may learn of your participation here and, because of this, may 
treat you unfairly or discriminate against you. For example, you could have problems 
getting or keepi[INVESTIGATOR_007] a job, or being accepted by [CONTACT_625136].   
• The in terviews that take place at some of your clinic visits will be computer -administered 
and questions of a personal nature may be asked. Responding to these questions may 
make you uncomfortable. You may choose not to answer any question that makes you 
uncomfo rtable.  
 
We will make every effort to protect your privacy and confidentiality during the study visits. Your 
visits will take place in private. Reports via computer or text messages will be stored in computers 
that are password -protected and will not inclu de personal information that could identify or link 
information to you; only your study ID number will be recorded. You will be shown how to erase 
the text message sessions from your mobile phone by [CONTACT_464]. However, as with all text 
messages sent from  and received on your phone, it is possible  that others may see your personal 
messages. Precautions  have been taken  to ensure that  questions asked via text message are 
vague and will not directly convey information about your  participation in this research  study.  
There is a possibility that you may exceed your cell phone plan limit and have to pay for that.  
 
When staff talk with you about how and when you used the study products they will audio record 
the discussion u sing a digital audio recorder. These aud io files will be reviewed and analyzed by 
[CONTACT_658202]. In addition, if you agree and are selected to participate in the in-depth interviews, 
these will be audio recorded.  The audio files will be put into writing by [CONTACT_658203].  
Any names that might be mentioned during the interview will NOT be retained.  Instead  a generic 
description will be used in the records (i.e., if you refer to a friend’s name, “FRIEND1” will be 
noted).  
 
Your audio recordings and any other information that links you to the research materials will be 
kept in a secure location that will be accessed only  by [CONTACT_625133] -035 study team for 
the purposes of this research. [Sites to modify with their site -specific source documentation 
storage duration requirements if required by [CONTACT_50812]/IECs: The audio recordings, notes, and 
transcripts from these materials will be kept for at least three years after the final study report  is 
submitted to the study sponso rs.] 
 
 
 
MTN -035, Version 1.0 87 June  15, 2018  
 What are possible benefits from taking part in this study?  
• There are no direct benefits for taking part in this study, but you or others may have future 
benefit from information learned in this study.  You may also learn more about HIV and 
other diseases and ways to protect yourself from acquiring HIV or other STIs .   
• You will have physical and rectal exams.  If these exams  show that  you might have any 
health problems, you will be told about medical care and other services available to you. 
This will be available to you even if you do not enroll in this study.  This study cannot 
provide you with general medical care, but study staff w ill refer you to other available 
sources of care , if needed .  
• You will get counseling and testing for HIV and STIs. If you have acquired an STI  other 
than HIV, you will be offered medicine to treat it or provided information for where you may 
receive treat ment, and study staff will discuss options available for counseling and 
treatment of your partner (s). This treatment or referral for treatment is available to you 
even if you do not enroll in this study.   
• If you acquire  HIV, you will need to receive care from your own health care provider or we 
will provide you with a referral. This study does not provide medication for treatment of 
HIV/AIDS.    
• You will receive free male condoms , if you need them.  
• You may receive free lubricant per local sta ndard of care.  
 
Will the study products  prevent HIV infection?  
The study products used in this study are placebos and do not contain any active drugs, so they 
will not prevent HIV.  There are other known effective ways to reduce your risk of contracting HIV: 
the use of condoms and/or the use of oral pre -exposure prophylaxis (PrEP) or post -exposure 
prophylaxis (PEP) medication . Truvada®  as a PrEP is an HIV prevention method in which people 
who do not have HIV take an oral tablet to reduce their risk of acquiring the virus . Study staff can 
provide you with additional information about PrEP and PEP if you are interested in learning more. 
If you are interested in these alternative options you may also wan t to discuss them with your 
doctor.   
 
What if there is new information learned during this study?  
We will tell you about new information from this or other studies that may affect your willingness 
to stay in this study.  You will also be told when study r esults may be available, and how to learn 
about them.  
 
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by 
[CONTACT_658204] -Funded Clinical Trial Information . This web  site will not 
include information that can identify you.  At most, the web  site will include a summary of the 
results.  You can search this web  site at any time.  
 
Is it possible that I may be taken out of the study without my consent?  
A study clinician may need  to remove you from the study early without your permission if:  
• The study is cancelled by [CONTACT_658205], the US Office for Human Research Protections 
(OHRP), MTN, government or regulatory agenc ies, or Institutional Review 
Board s/Independent Ethics Committees  (IRB/IEC). An IRB /IEC is a committee that 
watches over the safety and rights of research participants.  
• The Study Monitoring Committee (SMC) recommends that the study be stopped early . A 
SMC reviews the progress of the study and the kinds of effects that pe ople report while 
they are participating in the study . 
• You acquire  HIV (see “If You Acquire  HIV” section below) . 
 
 
MTN -035, Version 1.0 88 June  15, 2018  
 • (For individuals who can get pregnant ) You become pregnant (see “If You Become 
Pregnant ” section below) .  
• You report the use of non-study rectal medications or products, except personal lubricants 
and usual pre -RAI douches that do not contain N -9. 
• A study clinician decides that using the study  products  would be harmful to you, for 
example , you have a bad reaction to the study produ ct. 
• Other reasons that may prevent you from completing the study successfully, such as you 
are not able or willing to reliably keep appointments  or follow study rules . 
 
In the event that you are removed from or choose to leave this study for any reason, yo u will be 
asked to complete some of the procedures described for the Final/Early Termination Visit, if you 
are willing to do so.  
 
The study clinician will ask you to stop using the study products but continue to come in for follow -
up visits and procedures  if you have a bad reaction to the products.  
 
If You Acquire  HIV 
Your participation in this study will not cause HIV infection. However, there is always a chance 
that through sexual activity or other activities you may acquire  HIV. In the unlikely event that you 
acquire  HIV, study staff will give you counseling and refer you to available medical care and other 
services you may need. The study does not pay for this care. Tests may be performed that will 
allow your doctor to know  what HIV drugs would be best for the treatment of your type of HIV. If 
the HIV test shows that you have acquired  HIV, you will stop using the study products . You may 
be referred to other research studies. Continued study participation would be of no added  benefit 
to you, so your participation in the study will be discontinued.  
 
(For individuals who can get pregnant ) If You Become Pregnant  
The study products are not  birth control method s and will not prevent pregnancy . You must  use 
an effective method of contraception for at least 30 days (inclusive) prior to Enrollment  and for 
the duration of study participation . You must  agree to use an effective method of birth control such 
as birth control pi[INVESTIGATOR_625093] -based method, or an intrauterine device (IUD)  inserted 
at least [ADDRESS_887467] been 
sterilized (i.e.,  no longer able to become pregnant), and/or you only have sex that cannot lead to 
pregnancy (no penile -vaginal intercourse) .   
 
We do not know what effect the placebo study products may have  on pregnancy, including the 
effect on the fetuses of individuals  who use the products  when pregnant. Because of this, 
individuals  who are pregnant may not join this study. Individuals who can get pregnant and  who 
join this study will have pregnancy tests while in the study.  
 
If you become pregnant during the study, stud y staff will refer you to available medical care and 
other services you or your baby [CONTACT_439507]. The study does not pay for this care. You will stop 
using the study products  and you will exit the study.  
 
Will there be any payments if I take part in this rese arch study?  
[SITES TO INSERT INFORMATION ABOUT LOCAL REIMBURSEMENT:]  You will receive 
[SITES TO INSERT AMOUNT $xx] for your time, effort, and travel to and from the clinic at each 
scheduled visit. You may receive [ SITES TO INSERT AMOUNT $xx] for any visits  which occur 
in between your normally scheduled visits.  For responding to text messages, you will receive up 
 
 
MTN -035, Version 1.0 89 June  15, 2018  
 to [SITES TO INSERT AMOUNT $xx]. If you are selected and agree to take part in  the in -depth 
phone interview, you will receive [ SITES TO INSERT AMOU NT $xx]. 
 
What are the costs?  
[SITES TO COMPLETE ACCORDING TO SITE CAPACITY]  There is no cost to you for study 
related visits, physical/rectal exams, laboratory tests or other procedures. Treatments available 
to you from the study site for infections passe d through sex will be given to you free of charge or 
you will be referred for available treatment for the duration of the study.  
 
Are there any other studies if you cannot join this one?  
There may be other studies going on at this study clinic or in the c ommunity for which you may 
be eligible.  If you wish, we will tell you about other studies that we know about.  There may also 
be other places where you can go for HIV counseling and testing.  We will tell you about those 
places if you wish.  If you choose  not to take part in this study, it will have no effect on the regular 
medical care that is available to you at this clinic or elsewhere.  
 
Who will know about my participation in this research study?  
Any information about you obtained from this research wi ll be kept as private as possible.  All 
records related to your involvement in this research study will be kept in a [ SITE S TO INSERT ].  
Your identity on these records will be indicated by a number rather than by [CONTACT_138944], and the 
information linking these numbers with your name [CONTACT_625153].  
 
Efforts will be made to keep your information confidential. However, it is not possible to guarantee 
confidentiality. Your personal information may be disclosed if required by l aw. Any publication of 
this study will not use your name [CONTACT_107005].  The study staff may use your personal 
information to verify that you are not in any other research studies. This includes studies 
conducted by [CONTACT_658206].  
 
Your records may be reviewed by:  
• Study staff  
• Site IRBs/IECs  
• CONRAD, the organization that supplies the placebo insert  
• Representatives of the US Federal Government, including OHRP, NIH  and/or contractors of 
NIH 
• Other local,  US or international regulatory authorities  
 
[Sites to include/amend the following:]  [LOCAL/STATE/NATIONAL ] regulations require study 
staff to report the names of people who test positive for HIV and other infections passed during 
sex to the [LOCAL HEALTH AUTHORITY ]. Outreach workers from the [LOCAL HEALTH 
AUTHORITY ] may then contact [CONTACT_262330], since they also should be 
tested. If you do not want to inform your partners yourself, the outreach workers will contact [CONTACT_476], 
according to t he confidentiality guidelines of the [HEALTH AUTHORITY ]. 
 
[Sites to include/amend the following:]  
The researchers will do everything they can to protect your privacy. In addition to the efforts of 
the study staff to help keep your personal information priv ate, we have obtained a Certificate of 
Confidentiality from the US Federal Government. This Certificate protects study staff located in 
the US from being forced to tell people who are not connected with this study, such as the court 
system, about your part icipation or information you give for study purposes. However, if the study 
staff learns of possible child abuse and/or neglect or a risk of harm to you or others, they will be 
 
 
MTN -035, Version 1.0 90 June  15, 2018  
 required to tell the proper authorities. This Certificate does not prevent you from releasing 
information about yourself and your participation in the study.  
 
What if I am injured as a result of participating in this study?  
[SITES TO SPECIFY INSTITUTIONAL POLICY :] It is unlikely that you will be injured as a result 
of study participation. If you are injured, the [institution ] will give you immediate necessary 
treatment for your injuries. You [will/will not ] have to pay for this treatment. You will be told where 
you can receive additional treatment for your injuries. Th e U.S. National Institutes of Health (NIH) 
does not have a mechanism to pay money or give other forms of compensation for research 
related injuries. You do not give up any legal rights by [CONTACT_50841].  
 
May I withdraw my consent for participat ion in this research study?  
[SITE TO SPECIFY INSTITUTIONAL POLICY :] Taking part in this study is completely voluntary. 
You may choose not to take part in this study or leave this study at any time. If you choose not to 
participate or to leave the study, yo u will not lose the benefit of services to which you would 
otherwise be entitled at this clinic, nor will the confidentiality of the care provided for you here be 
affected.  You should feel free coming back to this facility even if you decide not to partic ipate in 
this study. If you want the results of the study after the study is over, let the study staff members 
know.  
 
What do I do if I have questions?  
If you ever have any questions about the study, or if you have a research -related injury, you 
should contact [insert name [CONTACT_50855]]  at [insert telephone 
number and/or physical address ]. 
 
If you have questions about your righ ts as a research participant, you should contact [insert name 
[CONTACT_420066]]  at [insert 
physical address and telephone number] . 
 
 
  
 
 
MTN -035, Version 1.0 91 June  15, 2018  
 SIGNATURES - VOLUNTARY CONSENT  
 
[INSERT SIGNATURE [CONTACT_625154] [CONTACT_625146]/IEC]: If you have 
read this consent form, or had it read and explained to you, and you understand the 
information, and you voluntarily agree to the study, please sign your name [CONTACT_420060].  
 
____________________ ______ __________________ ______________  
Participant Name   [CONTACT_625155]/Mark   Date  
(print)  
 
____________________ ________________________ ______________  
Study Staff Conducting  Study Staff Signature   [CONTACT_420064] (print)  
 
 
___________________ _ ________________________ ______________  
Witness Name (print)  Witness Signature    [CONTACT_658210] -035, Version 1.0 92 June  15, 2018  
 REFERENCES  
 
1. McGowan I. Microbicides for HIV prevention: Reality or hope? Curr Opin Infect Dis 
2010;23:26 -31. 
2. Leynaert B, Downs AM, de V, I. Heterosexual transmission of human immunodeficiency 
virus: variability of infectivity throughout the course of infection. European Study Group 
on Heterosexual Transmission of HIV. Am J Epi[INVESTIGATOR_5541] 1998;148:[ADDRESS_887468] risk of human immunodeficiency virus transmission between male sexual 
partners. Am J Epi[INVESTIGATOR_5541] 1999;150:306 -11. 
4. Gorbach PM, Manhart LE, Hess KL, Stoner BP, Martin DH, Holmes KK.  Anal 
intercourse among young heterosexuals in three sexually transmitted disease clinics in the 
[LOCATION_002]. Sex Transm Dis 2009;36:193 -8. 
5. Carlos JA, Bingham TA, Stueve A, et al. The role of peer support on condom use among 
Black and Latino MSM in th ree urban areas. AIDS Educ Prev 2010;22:[ADDRESS_887469] sex with men. Lancet 2012;380:[ADDRESS_887470] sex with men in North America, Western Europe, and Australia, 1996 -
2005. Ann Epi[INVESTIGATOR_5541] 2009;19:423 -31. 
8. WHO. HIV/AIDS Surveillance in Europe 2017 - 2016 data. The European Centre for 
Disease Prevention and Control (ECDC) and the  WHO Regional Office for Europe; 
2017.  
9. HIV among gay and bisexual men. CDC, 2018. (Accessed April 4, 2018, at 
https://www.cdc.gov/hiv/group/msm/index.html .) 
10. Stall R, Duran L, Wisniewski SR, et al. Running in Place: Implications of HIV Incidence 
Estimates among Urban Men Who Have Sex with Men in the [LOCATION_002] and Other 
Industrialized Countries. AIDS Behav 2009;13:615 -29. 
11. Millett GA, Jeffries WLt, Peterson JL, et al. Common roots: a contextual review of HIV 
epi[INVESTIGATOR_658165] w ith men across the African diaspora. Lancet 
2012;380:411 -23. 
12. HIV prevalence among South African MSM twice as high as general population. 2009. 
(Accessed October 26, 2017, at http://www.aidsmap.com/HIV -prevalence -among -South -
African -MSM -twice -as-high-as-general -population/page/1323795/ .) 
13. Baral SD, Poteat T, Stromdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden 
of HIV in transgender women: a systematic review and meta -analysis. Lancet Infect Dis 
2013;13:214 -22. 
14. Clark H, Babu AS, Wiewel EW , Opoku J, Crepaz N. Diagnosed HIV Infection in 
Transgender Adults and Adolescents: Results from the National HIV Surveillance 
System, 2009 –2014. AIDS Behav 2017;21:[ADDRESS_887471] JH, Jacobs ED, Finlayson TJ, McKleroy VS, Neumann MS, Crepaz N. Estimat ing 
HIV prevalence and risk behaviors of transgender persons in the [LOCATION_002]: a 
systematic review. AIDS Behav 2008;12:1 -17. 
16. Operario D, Soma T, Underhill K. Sex work and HIV status among transgender women: 
systematic review and meta -analysis. J Ac quir Immune Defic Syndr 2008;48:97 -103. 
 
 
MTN -035, Version 1.0 93 June  15, 2018  
 17. Organization WH. Consolidated guidelines on HIV prevention, diagnosis, treatment and 
care for key populations. In: HIV/AIDS Do, ed. Geneva, Switzerland2014.  
18. Schmidt A, Benvenuti S, Breveglieri M, et al ftEc. The European MSM internet survey 
(EMIS) UNGASS indicators2011.  
19. Abell N, Rutledge SE, McCann TJ, Padmore J. Examining HIV/AIDS provider stigma: 
assessing regional concerns in the islands of the Eastern Caribbean. AIDS Care 
2007;19:242 -7. 
20. Vu BN, Girault P, Do BV, Colby D, Tran LT. Male sexuality in Vietnam: the case of 
male -to-male sex. Sex Health 2008;5:[ADDRESS_887472] sex with men (MSM) 
in low -income and middle -income countries. J Acquir Immune Defic Syndr 2009;[ADDRESS_887473] 2:S143 -51. 
22. Blair JM, Fleming PL, Karon JM. Trends in AIDS incidence and survival among 
racial/ethnic minority men who have sex with men, U nited States, [ADDRESS_887474] 2002;31:339 -47. 
23. Sandfort TGM, Nel J, Rich E, Reddy V, Yi H. HIV testing and self -reported HIV status 
in South African MSM: Results from a community -based survey. Sex Transm Infect 
2008;84:425 -9. 
24. Hall HI, By[CONTACT_269957], Ling Q, Espi[INVESTIGATOR_103881] L. Racial/ethnic and age disparities in HIV 
prevalence and disease progression among men who have sex with men in the United 
States. Am J Public Health 2007;97:1060 -6. 
25. AIDS By [CONTACT_305226] -2016. 2016. (Accessed 10/21/ 2016, 2016, at 
http://www.unaids.org/en/resources/documents/2016/AIDS -by-the-numbers .) 
26. Weissman A, Ngak S, Srean C, Sansothy N, Mills S, Ferradini L. HIV Prevalence and 
Risks Associated with HIV Infection among Transgender Individuals in Cambodia. PLoS  
One 2016;11:e0152906.  
27. Chemnasiri T, Netwong T, Visarutratana S, et al. Inconsistent condom use among young 
men who have sex with men, male sex workers, and transgenders in Thailand. AIDS 
Educ Prev 2010;22:[ADDRESS_887475] sex 
with men – [LOCATION_002]2013.  
29. Casalino E, Choquet C, Leleu A, et al. Trends in condom use and risk behaviours after 
sexual exposure to HIV: a seven -year observational study. PLoS One 2014;9:e104350.  
30. Elford J. Changing patterns of sexual behaviour in the era of highly active antiretroviral 
therapy. Curr Opin Infect Dis 2006;19:[ADDRESS_887476] J, Bolding G, Davis M, Sherr L, Hart G. Trends in sexual behaviour among 
London homosexual men 1998 -2003: imp lications for HIV prevention and sexual health 
promotion. Sex Transm Infect 2004;80:[ADDRESS_887477] 
sex with men despi[INVESTIGATOR_419976] -induced viral suppression: analysis o f an 
extensively documented epi[INVESTIGATOR_901]. PLoS One 2013;8:e55312.  
33. Pi[INVESTIGATOR_240564], Gorbach PM, Weiss RE, et al. Acceptability of potential rectal microbicide 
delivery systems for HIV prevention: a randomized crossover trial. AIDS Behav 
2013;17:1002 -15. 
 
 
MTN -035, Version 1.0 94 June  15, 2018  
 34. Paz-Bailey G, Mendoza MC, Finlayson T, et al. Trends in condom use among MSM in 
the [LOCATION_002]: the role of antiretroviral therapy and seroadaptive strategies. AIDS 
2016;30:[ADDRESS_887478] sex with men: A 
cohort study. Lancet Infect Dis 2014;14:820 -9. 
36. Reece M, Herbenick D, Schick V, Sanders SA, Dodge B, Fortenberry JD. Condom Use 
Rates in a National Probability  Sample of Males and Females Ages 14 to 94 in the United 
States. The Journal of Sexual Medicine 2010;7:266 -76. 
37. Herbenick D, Reece M, Schick V, Sanders SA, Dodge B, Fortenberry JD. Sexual 
Behavior in the [LOCATION_002]: Results from a National Probabilit y Sample of Men and 
Women Ages 14 –94. The Journal of Sexual Medicine 2010;7:[ADDRESS_887479] Recent Male -Partnered Sexual Event among Gay and Bisexually 
Identifie d Men in the [LOCATION_002]. The Journal of Sexual Medicine 2011;8:3040 -50. 
39. Fonner VA, Dalglish SL, Kennedy CE, et al. Effectiveness and safety of oral HIV 
preexposure prophylaxis for all populations. AIDS 2016;30:[ADDRESS_887480] and treat: the strategic use of antiretroviral drugs to prevent HIV acquisition 
and transmission. AIDS 2010;[ADDRESS_887481] 4:S27 -39. 
41. Liu AY, Vittinghoff E, Chillag K, et al. Sexual risk b ehavior among HIV -uninfected men 
who have sex with men participating in a tenofovir preexposure prophylaxis randomized 
trial in the [LOCATION_002]. J Acquir Immune Defic Syndr 2013;64:[ADDRESS_887482] 2015;68:196 -203. 
43. Murnane PM, Heffron R, Ronald A, et al. Pre -exposure prophylaxis for HIV -1 prevention 
does not diminish the pregnancy prevention effectiveness of horm onal contraception. 
AIDS 2014;28:[ADDRESS_887483] sex with men. Lancet 2012;380:[ADDRESS_887484] ement HIV pre -exposure 
prophylaxis. Curr Opin HIV AIDS 2012;7:[ADDRESS_887485] 2013;62:334 -8. 
47. Mimiaga MJ, White JM, Krakower DS, Biello KB, Mayer KH. Suboptimal awareness 
and comprehension of published preexposure prophylaxis efficacy results among 
physicians in [LOCATION_005]. AIDS Care 2014;26:684 -93. 
48. [COMPANY_009]  Sciences. TRUVADA (emtricitabine and tenofovir disoproxil fumarate) tablets: 
Packge Insert (2016). 2016.  
49. Garg S, Goldman D, Krumme M, Rohan LC, Smoot S, Friend DR. Advances in 
development, scale -up and manufacturing of microbicide gels, films, and tab lets. 
Antiviral Res 2010;88:S19 -S29. 
50. Rosenberg ZF, Devlin B. Future strategies in microbicide development. Best Practice & 
Research Clinical Obstetrics & Gynaecology 2012;26:[ADDRESS_887486]. Unraveling th e divergent results 
of pre -exposure prophylaxis trials for HIV prevention. AIDS 2012;26:F13 -F9. 
52. Baeten JM, Haberer JE, Liu AY, Sista N. Pre -exposure prophylaxis for HIV prevention: 
where have we been and where are we going? Journal of acquired immune d eficiency 
syndromes (1999) 2013;63:S122 -S9. 
53. Brown E, Palanee -Philips T, Marzinke M, et al. Residual dapi[INVESTIGATOR_658166] -1 protection. AIDS 2016, July 
18-22, 2016, Durban, South Africa 2016:Abstract # TUAC0105LB.  
54. Ventuneac A, Carballo -Dieguez A, McGowan I, et al. Acceptability of UC781 gel as a 
rectal microbicide among HIV -uninfected women and men. AIDS Behav 2010;14:618 -
28. 
55. Carballo -Dieguez A, Dolezal C, Bauermeister JA, O'Brien  W, Ventuneac A, Mayer K. 
Preference for gel over suppository as delivery vehicle for a rectal microbicide: results of 
a randomised, crossover acceptability trial among men who have sex with men. Sex 
Transm Infect 2008;84:483 -7. 
56. Carballo -Dieguez A, Gig uere R, Dolezal C, et al. Rectal -specific microbicide applicator: 
evaluation and comparison with a vaginal applicator used rectally. AIDS Behav 
2014;18:1734 -45. 
57. Javanbakht M, Stahlman S, Pi[INVESTIGATOR_41274] J, LeBlanc MA, Gorbach PM. Prevalence and types 
of rectal  douches used for anal intercourse: results from an international survey. BMC 
Infect Dis 2014;14:95.  
58. Carballo -Dieguez A, Bauermeister JA, Ventuneac A, Dolezal C, Balan I, Remien RH. 
The use of rectal douches among HIV -uninfected and infected men who ha ve unprotected 
receptive anal intercourse: implications for rectal microbicides. AIDS Behav 
2008;12:860 -6. 
59. CONRAD. A 14 -Day Rectal Irritation and Pharmakinetic Study of Elvitegravir in 
Rabbits - Draft Pathology Report (MPI [CONTACT_226750]: 1645 -114). [ADDRESS_887487], Rubin CE. Human rectal mucosa: 
proctoscopic and morphological changes caused by [CONTACT_223687]. Gastroenterology 1977;72.  
61. Leyva FJ, Bakshi RP, Fuchs EJ, et al. Isoosmolar Enemas Demonstrate Preferential 
Gastrointestinal Distribution, Safety, and Acceptability Compared with Hyperosmolar 
and Hypoosmolar Enemas as a Potential Delivery Vehicle for Rectal Microbicides. AIDS 
Res Hum Retroviruses 2013;29:1487 -95. 
62. Yerkes EB, Rink RC, King S, Cain MP, Kaefer M, C asale AJ. Tap water and the Malone 
antegrade continence enema: a safe combination? The Journal of urology 2001;166:1476 -
8. 
63. Chemical IO, Kuznik J. Witepsol® H5 -based suppository products currently on the 
market. In: Rohan L, ed.2017.  
64. Stahlman S, Gor bach P. Rectal behaviors: a global overview.  Microbicides 2012. 
Sydney2012.  
65. Chakrapani V, Newman PA, Shunmugam M, et al. "Like Holding an Umbrella Before It 
Rains": Acceptability of Future Rectal Microbicides Among Men Who Have Sex With 
Men in India -A Modified Technology Acceptance Model. Qual Health Res 
2017;27:[ADDRESS_887488] Sex wit h Men and Transgender Women in Thailand: A Discrete Choice 
Experiment. AIDS Behav 2016;20:[ADDRESS_887489] Sex with Men in Tianjin, Chin a. PLoS One 
2016;11:e0156561.  
68. Brown J, Haines S, Wilding IR. Colonic spread of three rectally administered mesalazine 
(Pentasa) dosage forms in healthy volunteers as assessed by [CONTACT_658207]. 
Aliment Pharmacol Ther 1997;11:685 -91. 
69. Galea JT, K insler JJ, Imrie J, Nurena CR, Sanchez J, Cunningham WE. Rectal douching 
and implications for rectal microbicides among populations vulnerable to HIV in South 
America: a qualitative study. Sex Transm Infect 2014;90:[ADDRESS_887490] sex with men: a behavioral 
epi[INVESTIGATOR_658167]/STI prevention. Arch Sex Behav 
2014;43:[ADDRESS_887491] Sex wi th Men and Transwomen: Implications for Rectal 
Microbicides. AIDS Behav 2016;20:[ADDRESS_887492] sex with men in Brazil. BMJ Open 2017;7:e011122.  
73. Mitchell JW, Sophus AI, Lee JY, Petroll AE. Anal Douche Practices and Willingness to 
Use a Rectal Microbicide Enema for HIV Prevention and Associated Factors Among an 
Internet Sample of HIV -Negative and HIV -Discordant Male Couples in the US. AIDS 
Behav 20 16;20:[ADDRESS_887493] Sex 
with Men in Paris: Implications for HIV/STI Risk Behaviors and Rectal Microbicide 
Development. AIDS Behav 2017.  
75. Javanbakht M, Murphy R, Gorbach P, LeBlanc  M-A, Pi[INVESTIGATOR_41274] J. Preference and practices 
relating to lubricant use during anal intercourse: implications for rectal microbicides. 
Sexual Health 2010;7:[ADDRESS_887494] sex with men: the HIV prevention potential 
of a microbicidal gel. Am J Public Health 2000;90:1117 -21. 
77. Frasca T, Giguere R, Ibitoye M, et al. Lessons for Rectal Microbicide Development From 
an Acceptability Trial of a Placebo Gel Applied Prior to Receptive Anal Intercourse. 
Arch Sex Behav 2017;46:[ADDRESS_887495] Hum 
Retrovirol 1999;20:[ADDRESS_887496] sex with men (MSM) in Malawi, Namibia, and 
Botswana. PLoS One 2009;4:e4997.  
80. Gorbach PM, Weiss RE, Fuchs  E, et al. The slippery slope: lubricant use and rectal s
 exually transmitted infections: a newly identified risk. Sex Transm Dis 2012;39:[ADDRESS_887497] sex 
with men. Sex Transm Dis 2010;37:228 -33. 